PHILLY
Advanced Cell and Gene Therapy in Philadelphia

SAPA 美中藥協
Philadelphia 费城
sapagp.org



17-18 June, 2022
Sheraton Valley Forge Hotel
480 N Gulph Rd
King of Prussia, PA 19406

@PHILLY CELL AND GENE THERAPY ANNUAL CONFERENCE

This meeting brings together the innovators and business leaders to foster collaborations and advance cell and gene therapeutics in the Greater Philadelphia area

Scientific Track
Discovery, technology & application
Clinical & regulatory path
Chemistry manufacturing and control

CGT in China
Research & collaboration

@Philly Forum
Market dynamics
Policy, infrastructure
Entrepreneurship
Incubators, manufacture center

SELECT GREATER PHILADELPHIA COUNCIL

A WELCOME LETTER FROM CONFERENCE CO-CHAIRS

Dear Colleagues,

Welcome to the inaugural @Philly Cell and Gene Therapy Annual Conference!

For 30 years, scientists and entrepreneurs in the Greater Philadelphia area have been global leaders in the discovery and development of Cell and Gene Therapies (CGT). Most notably, four FDA-approved therapies have originated here, including the first cell therapy (Kymriah®) and the first gene therapy (Luxturna®). To celebrate these world-class innovations and the booming CGT industry in the region, the Sino-American Pharmaceutical Professionals Association-Greater Philadelphia (SAPA-GP) organized the @Philly Cell and Gene Therapy Annual Conference. By bringing together innovators and business leaders, the conference offers an excellent platform to foster scientific collaborations as well as business partnerships.

This conference also features an exciting @Philly Forum in collaboration with the Chamber of Commerce for Greater Philadelphia's Cell & Gene Therapy and Connected Health Initiative. The forum will allow you to leverage Greater Philadelphia's collective advantages in cell and gene therapy research, development, manufacturing, and entrepreneurship, especially in policy, infrastructure, and investment.

This 2-day in-person gathering is packed with trailblazing stories and expert-led discussions on topics from early discovery to local ecosystems that generate a rich supply of cell and gene therapy assets and talents. Please join us to extend a warm welcome to the plenary speaker Philip J. Brooks, PhD, who will present "NIH Collaborative Gene Therapy and Gene Editing Programs" on Friday morning; and the keynote speaker Peter Marks, MD, PhD, who will present "FDA's Efforts to Facilitate the Development of Cell and Gene Therapies" on Saturday morning.

In paying tribute to those courageous patients who have joined our journey in developing cell and gene therapies to fight devastating diseases, we are honored to feature "Seeking Cures for Cystic Fibrosis - Change Starts with One Person and One Community. Stories of Spirovant and Emily's Entourage" at the dinner session on Friday.

Please make sure to attend company showcases and visit the exhibit area to learn more about the latest offering of products and services from more than 25 companies. For business-minded individuals, we offer an entrepreneurship workshop and expert-led roundtables to discuss important business topics. If you are seeking career development opportunities, don't miss our company sponsored lunch sessions on talent recruitment. Please also come to our receptions at the end of each day for networking opportunities.

Finally, we would like to thank the organizing committee and our dedicated volunteers who have made this inaugural conference possible through their tireless efforts and meticulous execution. We would also like to express our deep appreciation towards our speakers, partners, and sponsors for your outstanding contribution and generous support.

Thank you and enjoy the conference!

Sincerely,

Haichen Yang, MD, MA, MBA
President, SAPA-GP 2022-23
Conference Co-chair
VP Clinical Research, Amicus Therapeutics

Jing Yang, PhD
Former President, SAPA-GP 2019-20
Conference Co-chair
CSO, BaseCure Therapeutic

SPONSORS


OBiO
和元生物


药明康德
WuXi AppTec


FORECYTE


WuXi ADVANCED THERAPIES
药明生基
药明康德
WuXi AppTec


GenScript
PROBIO


TeraImmune


SB
SinoBiological


ASCENDIA PHARMA


GenScript
Make Research Easy


20
ANNIVERSARY
GenScript
2002-2022


Bristol Myers Squibb™


ICON


Spark
THERAPEUTICS


AAVnerGene
Together We Find The Cures


Accurant Biotech


Alliance
PHARMA


FlowCam®


iview
THERAPEUTICS


MERCK


EXEGENESIS BIO


CUREport Inc.


Scheer Partners
A Reputation for Results


LIDE


NeuExcell
THERAPEUTICS


Amicus
Therapeutics®


GOODWIN


Medicilon


VCL LLP | LAW

@Philly CGT Annual Conference Day 1

A.M.	**Gene Therapy Discovery** Session 1: New Vision for AAV-Delivered Gene Therapies	**Chemistry, Manufacturing and Controls** Session 1: Current Challenges and Development Emphasis on CGT CMC
Company Sponsored Lunch Sessions		
P.M.	**Gene Therapy Discovery** Session 2: Innovation in Non-Viral Vectors in Gene Therapies Session 3: RNA Therapeutics on The Horizon	**Chemistry, Manufacturing and Controls** Session 2: Elite Process Development and Tech Transfer Strategy: Pace and Robustness Session 3: High-Quality CGT Drug Manufacturing
RECEPTION		
DINNER: Featured Conversation: Seeking Cures for Cystic Fibrosis		

@Philly CGT Annual Conference Day2

A.M.	**Next Generation Cell Therapy** Session 1: Novel Antigens for CAR-T Beyond Blood Cancer Applications	**Clinical Development and Regulatory** Session 1: Unique Challenges in CGT Clinical Programs
Company Sponsored Lunch Sessions		
P.M.	**Next Generation Cell Therapy** Session 2: Latest Advancement in Cell Therapies Session 3: Overcoming the Immunogenicity Challenges for Cell Therapies	**Clinical Development and Regulatory** Session 2: Regulatory Pathways for Advancing CGT Products Session 3: Bioanalysis and Evaluation of PK/PD in CGT Clinical Studies
RECEPTION		

June 17th 2022 OPENING SPEECH

@Philly Forum	CGT in China
Session 1: Market Dynamics & Nurturing CGT Startups in the Greater Philadelphia Area	Mapping a Success Strategy to Access CGT Market in China

Company Sponsored Lunch Sessions

@Philly Forum	Expert-Led Roundtable
Session 2: Greater Philadelphia's World-class Incubators, Research and Manufacture Centers Session 3: Policies and Initiatives to Support CGT in the Greater Philadelphia Area	Session 1: Working with Existing Investors, Becoming "IPO Ready", Handling the IPO Process Session 2: Accounting and Tax Considerations of Young Companies, Selecting the Right Partners

RECEPTION

- Change Starts with One Person and One Community

June 18th 2022 KEYNOTE SPEECH

Oncolytic Virus – Session Sponsored by OBiO Technology	Company Showcase	Expert-Led Roundtable
Clinical Trials and Innovations	Session 1: iVIEW Therapeutics; GenScript ProBio US; Frontage Laboratories	Session 3: Establish & Custom-Built Lab Spaces, cGMP Manufacturing Suites and Specialty Labs

Company Sponsored Lunch Sessions

Entrepreneurship Workshop	Company Showcase	Expert-Led Roundtable
Session 1: Mini Bootcamp: From Idea to Initiating a Startup Session 2: World Cafe Chat - Networking, Q&A	Session 2: Sino Biological; Forecyte Bio; Ascendia Pharmaceuticals	Session 4: Legal Considerations of US-China Cross Border Transaction and Technology Transfer Session 5: Accelerated Ride of Venture Development-Perspective for Scientific Founders

RECEPTION

AGENDA Friday, June 17th, 8:00 a.m.-9:00 p.m.

8:00-8:50 a.m. Check in and Breakfast

Plenary Session	Grand Ballroom
8:50-8:55 a.m.	**Welcome**
Session chair:	Haichen Yang, President of SAPA-GP 2022-23; Conference Co-Chair; Vice President, Clinical Research, Amicus Therapeutics
8:55-9:05 a.m.	**Opening Remarks: Why Philly for CGT? Because Innovation is in Our Bones** Frederick (Rick) Jones, Partner, BioAdvance
9:05-9:45 a.m.	**NIH Collaborative Gene Therapy and Gene Editing Programs** Philip J (P.J.) Brooks, Acting Director, Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences, NIH
9:45-10:00 a.m.	**Coffee Break**

10:00-11:30 a.m. Parallel Sessions

Gene Therapy Discovery	Centennial Ballroom 1
Session 1: New Vision for AAV-Delivered Gene Therapies	
Session chair:	Jill Weimer, Chief Scientific Officer, Amicus Therapeutics
10:00-10:30 a.m.	**Gene Replacement 2.0: Engineering Next-Generation Gene Therapies for Enhanced Efficacy** Jill Weimer, Chief Scientific Officer, Amicus Therapeutics
10:30-11:00 a.m.	**AAV-Based Hemophilia A Gene Therapy** Qizhao Wang, Chief Technology Officer, AAVnerGene Inc
11:00-11:30 a.m.	**Strategies to Reduce AAV Impurity and Increase Infectivity in AAV Vector Production** Chunping Qiao, Principal Scientist, RegenXBio

Chemistry, Manufacturing and Controls (CMC)	Centennial Ballroom 2&3
Opening Remark:	Lu Wang, Conference Program Director & CMC Track Lead; Downstream Process Development Lead, Spark Therapeutics
Session 1: Current Challenges and Development Emphasis on CGT CMC	
Session chair:	Jin Wen, Conference Marketing/Promotion Lead & CMC Track Co-Lead; Analytical Development Scientist, Spark Therapeutics
10:00-10:30 a.m.	**Phase Appropriate CGT Manufacturing and Comparability** Xiaoping Dai, Senior Vice President; Chief Technology Officer, IVERIC Bio
10:30-11:00 a.m.	**Bac/sf9, A Promising System for AAV Manufacturing in Industry**

Jingmin Zhou, Chief Executive Officer, Genemagicbio

11:00-11:30 a.m. **E:F Ratio Analysis Methodologies for AAV-Based Gene Therapies**

John MacNair, Analytical Program Lead, Spark Therapeutics

@Philly Forum Grand Ballroom

Session 1: Market Dynamics & Nurturing CGT Startups in the Greater Philadelphia Area

Session chair: Jing Yang, Conference Co-Chair; Chief Scientific Officer, BaseCure Therapeutics

10:00-10:30 a.m. **Biopharma Business Development, Licensing, Funding, and M&A through 2022: Focus on Cell and Gene Therapy in Philadelphia**
Chris Dokomajilar, Founder; Chief Executive Officer, Dealforma

10:30-10:45 a.m. **Bringing Investment Dollars to Philadelphia and Cultivating Cell & Gene Therapy Spinouts from Academia**
Carter Caldwell, Penn Medicine Co-Investment Program Director, University of Pennsylvania

10:45-11:00 a.m. **Mining the Gems from the Technology Transfer Perspectives**

Stephen G. Nappi, Associate Vice President, Technology Commercialization and Business Development, Temple University

11:00-11:30 a.m. **Panel Discussion and Q&A**

Moderator: Patrick Deng, Senior Director, Finance Controller, AstraZeneca

CGT in China Kiosk Room

Mapping a Success Strategy to Access CGT in China

Session chair: Fang Shen, Vice President, Immunome

10:00-10:30 a.m. **Develop and Commercialize Relma-cel in China: JW's Journey from Zero to One**
James Li, Co-Founder; Chief Executive Officer, JW Therapeutics

10:30-11:00 a.m. **Neuroregenerative Gene Therapy and Its Applications**

Gong Chen, Co-Founder; Chief Scientific Officer, NeuExcell Therapeutics

11:00-11:30 a.m. **Key Considerations of the GCT Landscape in China**

Guodong Jia, Chief Executive Officer, OBiO Technology

11:30 a.m.-12:00 p.m. **Building China-US Partnerships in Cell and Gene Therapy**

Mahen Gundecha, Chief Business Officer, Exegenesis Bio

11:30 a.m.-1:00 p.m. **Lunch Break and Networking**

Sponsored Lunchtime Conversation with WuXi AppTec LTD Frazer

Session chair:	Xuguang Chen, Lead Scientist, Spark Therapeutics
11:45 a.m.-12:45 p.m.	**WuXi AppTec's Comprehensive DMPK and Bioanalytical Services at US** Sharon Tong, Executive Director and US New Jersey Site Head, WuXi AppTec

Sponsored Lunchtime Conversation with GenScript — Malvern

Session chair:	Yangzhou (Mirina) Li, Regulatory Affairs Manager
11:45 a.m.-12:45 p.m.	**GenScript Company Overview** GenScript HR Team

1:00-2:30 p.m. Parallel Sessions

Gene Therapy Discovery — Centennial Ballroom 1

Session 2: Innovation in Non-viral Vectors in Gene Therapy

Session chair:	My G. Mahoney, Professor, Thomas Jefferson University
1:00-1:30 p.m.	**The Novel Strategy and Promising Development in LNP Innovations for Gene Delivery** Demin Zhu, President; Chief Executive Officer, Cureport
1:30-2:00 p.m.	**Blood-derived Exosomes as Predictive Cancer Biomarkers for Immune Checkpoint Inhibitor Therapy** My G. Mahoney, Professor, Thomas Jefferson University

Chemistry, Manufacturing and Controls (CMC) — Centennial Ballroom 2&3

Session 2: Elite Process Development and Tech Transfer Strategy: Pace and Robustness

Session chair:	Ohnmar Khanal, Senior Scientist, Spark Therapeutics
1:00-1:30 p.m.	**Lab Automation to Turbocharge the Gene Therapy R&D Engine** Marc Wenger, Head of HT Technology and Lab Automation, Spark Therapeutics
1:30-2:00 p.m.	**Elite from the Get-go: Early Process and Product Understanding Drives Gene Therapy Success** Tatiana Nanda, Head of Cell and Gene Drug Product Development, Center for Breakthrough Medicines
2:00-2:30 p.m.	**Pre-Clinical AAV Production and Optimization: Not As Easy As It Looks** Steven Hughes, Director of New Platform Development, Genscript

@Philly Forum — Grand Ballroom

Session 2: Greater Philadelphia's World-Class Incubators, Research, and Manufacture Centers

Session chair:	Lisa Berger Baskin, Senior Vice President, Scheer Partners, Inc

Lightning Round

1:00-1:10 p.m.	**Center for Breakthrough Medicines:** The First Complete CDMO Solution for the Development and Commercialization of Cell and Gene Therapies Audrey Greenberg, Co-Founder; Chief Business Officer, Center for Breakthrough Medicines
1:10-1:20 p.m.	**University City:** The Heart of Philadelphia's Innovation District - Where World Renowned Academics, Corporations and Innovators Collide Tracy S. Brala, Senior Vice President, Strategy and Partnerships, University City Science Center
1:20-1:30 p.m.	**Pennsylvania Biotechnology Center:** One of the Nation's Most Successful Life Sciences Incubators Louis Kassa, Executive Vice President; Chief Operating Officer, Pennsylvania Biotechnology Center of Bucks County
1:30-1:40 p.m.	**Philadelphia Industrial Development Corporation:** Philadelphia – Recipe for Biotech Success Thomas Dalfo, Senior Vice President, Real Estate Services, Philadelphia Industrial Development Corporation
1:40-2:30 p.m.	**Panel Discussion and Q&A** Moderator: Yang Yuan, SAPA-GP President-Elect; Conference Program Director; Senior Principal Scientist, BMS

Expert-Led Roundtable — Berwyn

Session 1: Working with Existing Investors, Becoming "IPO Ready", Handling the IPO Process

1:00-2:30 p.m. **Strategies and Considerations for VC and PE Financing Leading to IPO**

- Does and Doesn't with Investors as a Private or Public Company
- How to Be "IPO Ready"
- Manage the IPO Process

Ding Ding, Former Head of APAC Healthcare Investment Banking and Capital Markets at Credit Suisse.

2:30-2:45 p.m. **Coffee Break**

2:45-4:15 p.m. Parallel Sessions

Gene Therapy Discovery — Centennial Ballroom 1

Session 3: RNA Therapeutics on the Horizon

Session chair:	Jun He, Gene Therapy Track Lead; Assistant Professor, Thomas Jefferson University
2:45-3:15 p.m.	**Modulating Splicing to Target Hepatocellular Carcinoma** Hien Dang, Chief of the Division of Surgical Research, Assistant Professor, Thomas Jefferson University
3:15-3:45 p.m.	**RNA Therapeutics with LEAPER 2.0: Initial Proof of Concept in Preclinical Models** Bo Zhang, Head of US Subsidiary, EdiGene Inc.

Chemistry, Manufacturing and Controls (CMC) — Centennial Ballroom 2&3

Session 3: High Quality CGT Drug Manufacturing

Session chair: John Easson, Process Science Leader, Spark Therapeutics

2:45-3:15 p.m. **Quality at Forecyte Bio: It Starts at the Top**

James Boykin, Senior Director of QA, Forecyte Bio USA Limited

3:15-3:45 p.m. **Process Development of Viral Vector Platforms for cGMP Manufacturing**

Man-shiow Jiang, Executive Director, Viral Vector, Cell MFG-PD, WuXi Advanced Therapies

3:45-4:15 p.m. **Panel Discussion**

Moderator: Matt Petroff, HT Downstream and Formulation Dev Lead, Spark Therapeutics

@Philly Forum Grand Ballroom

Session 3: Policies and Initiatives to Support Cell and Gene Therapy in the Greater Philadelphia Area

Session chair: Wei-chung Bryan Tsao, Manager, Life Science and Healthcare Initiatives at Chamber of Commerce for Greater Philadelphia

2:45-3:05 p.m. **The Cell & Gene Therapy and Connected Health Initiative in Greater Philadelphia**
Claire Greenwood, Executive Director, CEO Council for Growth

3:05-3:20 p.m. **Why Philadelphia? Understanding the Opportunities in A Rapidly Accelerating Biotech Cluster**
Joseph Fetterman, Executive Vice President, Healthcare Services, Colliers International

3:20-3:40 p.m. **Incentivizing Innovation – Advocating for Policies that Encourage Life Sciences Growth in Pennsylvania**
Kurt Imhof, Vice President, Policy & Public Affairs, Life Sciences Pennsylvania

3:40-4:15 p.m. **Panel Discussion**

Moderator: Rachael Hao, Conference Program Director & @Philly Forum Track Lead; Associate Director, Merck

Expert-Led Roundtable Berwyn

Session 2: Accounting and Tax Considerations of Young Companies, Selecting the Right Partners

2:45-4:15 p.m. **Topics:**

- Growth Strategy, Industry Trends, and How We can Help – limitations of current therapies, status of current funding in market, and development outside of oncology
- Accounting Function and IPO Process – early day accounting, importance of accurate books & records for future capital raises, and Emerging Growth Company requirements
- Tax Considerations – compliance and planning
- Selecting the Right Partners / Service Providers

Varun Renjen, Managing Director, Life Science Strategy, KPMG LLP

Ryan Breen, Managing Director, Audit, KPMG LLP

Rui Che, Managing Director, KPMG LLP

4:30-5:30 p.m.	**Reception**	
6:00-9:00 p.m.	**Dinner**	Grand Ballroom

Featured Conversation: Seeking Cures for Cystic Fibrosis - Change Starts with One Person and One Community: Stories of Spirovant and Emily's Entourage

Jessica Lee, Head, Clinical Science and Operations, Spirovant Sciences

Emily Kramer-Golinkoff, Co-Founder, Emily’s Entourage

Moderator: Jing Yang, Conference Co-Chair; Chief Scientific Officer, BaseCure Therapeutics

AGENDA Saturday, June 18th, 8:15 a.m.-5:30 p.m.

8:15-9:00 a.m. Check in and Breakfast

Keynote Speech	Grand Ballroom
Session chair:	Haichen Yang, President of SAPA-GP 2022-23; Conference Co-Chair; Vice President, Clinical Research, Amicus Therapeutics
9:00-9:45 a.m.	**FDA's Efforts to Facilitate the Development of Cell and Gene Therapies** Peter Marks, Director, Center for Biologics Evaluation and Research (CBER), FDA
9:45-10:00 a.m.	**Coffee Break**

10:00-11:30 a.m. Parallel Sessions

Next Gen Cell Therapy	Centennial Ballroom 1
Session 1: Novel Antigens for CAR-T Beyond Blood Cancer Applications	
Session chair:	Tao Niu, Next Gen Cell Therapy Track Lead; Associate Director, Clinical & Quantitative Pharmacology, Vertex Pharmaceuticals
10:00-10:30 a.m.	**CDH17CAR T Cells Eliminate Gastrointestinal Cancers without Toxicities to Healthy Cells** Xianxin Hua, Professor, University of Pennsylvania
10:30-11:00 a.m.	**Intestinal Proteins as Safe CAR-T Cell Therapy Targets for GI Cancers** Adam Snook, Associate Professor, Thomas Jefferson University
11:00-11:30 a.m.	**Panel Discussion** Moderator: Tao Niu, Next Gen Cell Therapy Track Lead; Associate Director, Clinical & Quantitative Pharmacology, Vertex Pharmaceuticals

Clinical Development and Regulatory	Grand Ballroom
Session 1: Unique Challenges in CGT Clinical Programs	
Session chair:	David Weinstein, Senior Vice President, Clinical Development, Passage Bio.
10:00-10:30 a.m.	**Regulatory Requirements and Challenges in Clinical Development Programs for Cell and Gene Therapies in Oncology** Andreas Dreps, Senior Vice President, Oncology Drug Development Services, ICON plc
10:30-11:00 a.m.	**Gene Therapy for Treatment of Neurodegenerative Diseases: Approaches and Challenges** David Weinstein, Senior Vice President, Clinical Development, Passage Bio.
11:00-11:30 a.m.	**RNAi Therapeutics for Cardiovascular and Metabolic Diseases: The Start of a New Age** Weinong Guo, Senior Vice President, Clinical Research, Alnylam Pharmaceuticals Inc.

Oncolytic Virus – Session Sponsored by OBiO	Centennial Ballroom 3

Clinical Trials and Innovations

Session chair: Dongjin Fu, Director, Johnson & Johnson.

10:00-10:30 a.m. **The Progress of Oncolytic Virus Drug Developnlent via OvPENS Platform**
Grace Zhou, Chief Executive Officer; Chief Scientific Officer, ImmVira

10:30-11:00 a.m. **Oncolytic Virotherapy: Turning Anti-Viral Immunity to Anti-Cancer**

William Jia, Co-Founder; Chief Scientific Officer, Virogin Biotech

11:00-11:30 a.m. **Combination Treatment Solution of Oncolytic Virus Therapy and CAR-T Cell Therapy in Solid Tumor**
Yang Nan, Vice President, Business Development, PersonGen BioTherapeutics (Suzhou)

Company Showcase Centennial Ballroom 2

Session 1: iVIEW Therapeutics; GenScript ProBio US; Frontage Laboratories

Session chair: Yufeng Li, Executive Director, Qilu Pharma

10:00-10:30 a.m. **Innovative Therapy for Eye Disease**

Bo Liang, Chief Executive Officer, iVIEW Therapeutics

10:30-11:00 a.m. **Optimizing Manufacturing Process for AAV Plasmid with ITR**

Mark Thompson, Senior Business Development Manager, GenScript ProBio USA
Lan Tang, Reginal Business Development Head, GenScript ProBio USA

11:00-11:30 a.m. **Establishing GLP-Compliant Genomics Services**

Bin Xu, Associate Director, Frontage Laboratories

Expert-Led Roundtable Berwyn

Session 3: Establish and Custom-Built Lab Spaces, cGMP Manufacturing Suites and Specialty Labs

10:00-11:30 a.m. **Topics:**

- Establish and Custom-Built Lab Spaces
- cGMP Manufacturing Suites and Specialty Labs

Tim Conrey, Principal, Senior Vice President, Scheer Partners

Lisa Baskin, Senior Vice President, Scheer Partners

11:30 a.m.-1:00 p.m. **Lunch Break and Networking**

Sponsored Lunchtime Conversation with BMS. Centennial Ballroom 2

11:45 a.m.-12:45 p.m. **Panel Discussion: Realizing Your Potential in Biopharma**

Daniel Zhu, Director, Lead Product Safety Physician, BMS

Yan Serena Jin, Associate Director, Procurement Strategic PMO and Transformation, BMS
Dharmesh Patel, Director, Biospecimen Planning Lead, BMS

Mihika Bhatt, Senior Manager; Senior Principal Engineer, CTDO Manufacturing, Global MS&T, BMS
Zhen Tong, Senior Manager, Principal Process Engineer, BMS

Mandy Xie, Executive Director, CT Product & Analytical Development • Cell Therapy Tech Dev, BMS
Moderator: Jennifer Rasing, PAN PBRG Global Lead, BMS

Sponsored Lunchtime Conversation with Accurant Biotech Frazer

Session chair: Yuan Yuan, Scientist, Teva Pharmaceuticals

11:45 a.m.-12:45 p.m. **The Management of Immunogenicity Program in Cell and Gene Therapies**
Dongbei Li, President, Accurant Biotech

1:00-2:30 p.m. Parallel Sessions

Next Gen Cell Therapy Centennial Ballroom 1

Session 2: Latest Advancement in Cell Therapies

Session chair: Yixuan Ming, Scientist, Spark Therapeutics

1:00-1:30 p.m. **Scalable Manufacturing of Engineered Treg Cells for Vein-to-Vein Processes**
Jihoon (Jay) Park, Chief Operating Officer, TeraImmune

1:30-2:00 p.m. **Ciltacabtagene Autoleucel for Relapse and Refractory Multiple Myeloma**

Yuhong Qiu, Vice President, Regulatory Affairs, Legend Biotech

Clinical Development and Regulatory Grand Ballroom

Session 2: Regulatory Pathways for Advancing CGT Products

Session chair: Li Wan, Senior Vice President; Head of Global Regulatory Affairs, Genequantum Healthcare

1:00-1:30 p.m. **FDA's Clinical Regulatory Perspective: Designing First-In-Human Trials for Cellular and Gene Therapy Products**
Chaohong Fan, Team Leader and Acting Branch Chief at the Malignant Hematology Branch, Office of Tissues and Advanced Therapies (OTAT), CBER

1:30-2:00 p.m. **Regulatory Considerations for Early Development of Gene Therapies**

Eva Essig, Independent Regulatory Consultant

2:00-2:30 p.m. **Current Regulatory Landscape of Gene Therapy Product Development and Approval**
Jim Wang, Chief Regulatory Officer, Adverum Biotechnologies

Entrepreneurship Workshop — Centennial Ballroom 3

Mini Bootcamp: From Idea to Initiating a Startup

Session chairs: David Cragin, Entrepreneurship Workshop Track Lead; Director, Merk & Co.,
Dennis M. Gross, CEO, Pennsylvania Drug Discovery Institute,
Huize Yan, Entrepreneurship Workshop Track Lead; Scientist, Spark Therapeutics

1:00-1:10 p.m. **Open Remarks**

Sarah Steltz, Vice President, Economics Competitiveness, Philadelphia Chamber of Commerce

1:10-1:40 p.m. **A Brief Overview of The Continuum of Funding**

Dennis M. Gross, CEO, Pennsylvania Drug Discovery Institute

1:40-2:10 p.m. **Strategic Approach to an Intellectual Property Portfolio**

Patrick Kelly, Counsel, Stradley Ronon

2:10-2:40 p.m. **What Do You Need to Know to Get Your Company off the Ground?**

Wendy Pan, Partner, Goodwin Procter LLP

Company Showcase — Centennial Ballroom 2

Session 2: Sino Biological; Forecyte Bio; Ascendia Pharmaceuticals

Session chair: Patrick Liu, Co-founder; President, Cure Genetics Co., Ltd.

1:00-1:30 p.m. **Atlas of Recombinant Proteins and Antibodies for Cell Therapy Discovery**

Sumana Sundaramurthy, Technical Account Manager, Sino Biological US Inc.

1:30-2:00 p.m. **Forecyte Bio - Your Trusted Full-Service CGT CDMO Company**

Shuyuan Zhang, Chief Technology Officer, Forecyte Bio Limited

2:00-2:30 p.m. **Drug Delivery Technologies for Gene Therapy**

Jim Huang, Chief Executive Officer, Ascendia Pharmaceuticals

Expert-Led Roundtable — Berwyn

Session 4: Legal Considerations of US-China Cross Border Transaction and Technology Transfer

1:00-2:30 p.m. **Legal Risks and Considerations of US-China Cross Border Transaction and Technology Transfer**
Bin Hu Karg, Partner, VCL Law

Fang Liu, Partner, VCL Law

2:30-2:45 p.m. **Coffee Break**

2:45-4:15 p.m. Parallel Sessions

Next Gen Cell Therapy — Centennial Ballroom 1

Session 3: Overcoming the Immunogenicity Challenges for Cell Therapies

Session chair: Yanchun Li, Senior Research Investigator, Gene Therapy Program, University of Pennsylvania

2:45-3:15 p.m. **Overcoming the Immunogenicity Challenges of Cell Therapies**

Vibha Jawa, Executive Director, BMS

3:15-3:45 p.m. **Clinical Relevance of Immunogenicity Testing for Cell Therapy**

Weifeng Xu, Director, Merck

3:45-4:15 p.m. **Immunogenicity Assessment of Autologous CAR-T Cell Therapies**

Tong-yuan Yang, Senior Director, Janssen R&D

Clinical Development and Regulatory — Grand Ballroom

Session 3: Bioanalysis and Evaluation of PK/PD in CGT Clinical Studies

Session chair: Yan G. Ni, Executive Director of Biomarkers and Precision Medicine, Passage Bio

2:45-3:15 p.m. **Challenge and Trends of Diagnostic Testing for Patient Selection in Rare Disease Clinical Trials**
Yan G. Ni, Executive Director of Biomarkers and Precision Medicine, Passage Bio

3:15-3:45 p.m. **Translational and Clinical PK/PD of In Vivo Gene Therapy for Rare Diseases**
Tao Niu, Associate Director, Clinical & Quantitative Pharmacology, Vertex Pharmaceuticals

3:45-4:15 p.m. **qPCR and ddPCR Application in Bioanalysis of Gene and Cell Therapeutic Products**
Clara Brando, Associate Director, Large Molecules, Bioanalytical Services Business Unit, Lab Testing Division, WuXi AppTec

Entrepreneurship Workshop — Centennial Ballroom 3

World Cafe Chat - Networking, Q&A

2:50-3:20 p.m. **Entrepreneurship – A Journey of Discovery and Action**

Richard H. Smith, Chief Operation Officer, Rockland Immunochemicals, Inc

3:20-4:00 p.m. **Breakout Tables Q&A**

Expert-Led Roundtable — Berwyn

Session 5: Accelerated Ride of Venture Development - Perspective for Scientific Founders

2:45-4:15 p.m.	**Accelerated Ride of Venture Development - Perspective and Check Box for Scientific Founders** • Entrepreneurs' Vision vs. Scientists' Idea • Partnership Value vs. Cap Table Management • Exit Strategies: M&A, Licensing and Alternative Listing - IPO vs.SPAC Henry Lu, Partner, NBS CAP
4:30-5:30 p.m.	**Reception**

CONFERENCE ORGANIZING COMMITTEE

Conference Co-Chairs

Haichen Yang Jing Yang

Program Directors

Rachel Hao Lu Wang Yang Yuan

Program Track Leads

David Cragin	Dennis M Gross	Ruixin (Rachel) Hao	Jun He	Tao Niu	Yun Liu
Weimin (Bill) Lu	Fang Shen	Lu Wang	Xiaomei Wang	Xin (Jerry) Xin	Yizhen Xu
Huize Yan	Haichen Yang	Jing Yang	Rui Zhang		

Session Chairs

Lisa Berger Baskin	Xuguang Chen	David Cragin	Patrick Deng	John Easson	Dong Fu
Dennis M Gross	Ruixin (Rachel) Hao	Jun He	Ohnmar Khanal	Yanchun Li	Yufeng Li
Patrick Liu	My G Mahoney	Yixuan Ming	Yan G. Ni	Tao Niu	Fang Shen
Wei-chung (Bryan) Tsao	Li Wan	Jill Weimer	David Weinstein	Jin Wen	Huize Yan
Haichen Yang	Jing Yang	Yang Yuan	Yuan Yuan		

Conference Management Team

Qishui (Tracy) Chen	Pengbo Guo	Sheng Hu	Coco Li	Stella Si	Hui Wang
Jin Wen	Sherry Wang	Di Wu	Saisi Xue	Xinjun Zhang	

Conference Volunteer Team

Qimin Chao	Selina Chen	Zhiyi Cui	Yiwei Du	Yifan Gong	Howard Guo
Dian He	Namila	Yuxin Hu	Victoria Huang	Jerry Jia	Tianying Jiang
Yanchun Li	Yangzhou Li	Minmin Liu	Wenbin Liu	Zhongwen Luo	Yangsi Ou
Wang Qi	Elsie Shen	Xiaowei Sun	Oliver (Xin) Tong	Yifang Wang	Shihan Xu
Yizhen Xu	Linxuan Yan	Yang Ying	Nancy Yu	Yuan Yuan	Tianhua Zhai
Gavin Zhang	Marilyn Zhou	Ronghui Zhou	Xiaonan Liu	Howard	Ginger (Zhujun)
Feifei					

SPEAKERS

Lisa Baskin

SVP
Scheer Partners

Industry veteran Lisa Berger Baskin has had an impressive and highly diverse 30+ year career in commercial real estate that includes 14 years heading her own brokerage and serving as General Partner for the Marketplace at East Falls in Philadelphia. Focused on client satisfaction, she has been deeply involved in a wide range of hands-on roles from negotiating complex biotech leases, consolidations, disposition of assets, to handling zoning and financial analyses. Ms. Baskin has directed projects in both California and Pennsylvania including a redevelopment of a 100,000 sq. ft. industrial project in Philadelphia. Ms. Baskin continues to maintain her WBE certified by the Women's Business Enterprise National Council (WBENC). A native Pennsylvanian raised in Montgomery County; she holds a Bachelor of Science degree in accounting from Pennsylvania State University.



James Boykin

Sr. Director, Quality Assurance
Forecyte Bio Limited (US)

James has over 20 years of experience in quality systems with extensive GMP knowledge. He joined Forecyte Bio (US) in February 2022 and oversees the QA team supporting GMP manufacturing. Previously, James was at AstraZeneca and Vigene Biosciences where he held QA positions of increasing responsibilities. James holds a bachelor's degree in Chemistry from University of Southern Maine and was certified as both an ASQ Quality Manager and Quality Auditor. He also proudly served in the US Navy for 4 years.

Tracy S. Brala, M.B.A.

Senior Vice President, Strategy and Partnerships
University City Science Center

Tracy S. Brala is the Senior Vice President of Strategy and Partnerships for the University City Science Center and leads the strategy, marketing, corporate development, and customer experience functions. Previously, Tracy was the VP of Ecosystem Development, a role she created to encompass her team's work of convening, galvanizing, and amplifying an inclusive Philadelphia innovation ecosystem. Tracy came to the Science Center from Comcast where she served as the Executive Director for Growth & Strategy for Xfinity services. Tracy's experience also includes the founding of her own consulting company to help businesses grow through product and business development, branding, and marketing. She earned a BS, Accounting from Villanova University and an MBA from The Wharton School at the University of Pennsylvania. Tracy has served as the President of the Villanova University Alumni Association Board of Directors, on the Villanova University President's Advisory Council and founded the Villanova University Alumni Diversity and Inclusion Task Force. She currently is on the Board of the Forum of Executive Women and Chair of its DEI Committee, is a member of the University City District Board, on the Anne Welsh McNulty Women's Leadership Institute Board and on the PHL CVB Life Sciences Advisory Board.

Clara Brando, Ph.D.

Associate Director, Large Molecules, Bioanalytical Services Business Unit
Lab Testing Division, WuXi

Clara Brando received her Pharma Doctor and her Ph.D. in immunology/Immuno-pathology from the University of Turin (Italy) in 1990. She received post-doctoral training at the Laboratory of Immunology at the National Institute of Allergic and Infectious Disease (NIAID) at NIH from 1990-94. During this time, Brando was trained in Cellular immunology with emphasis on T cell response
Brando has served as a senior scientist at Temple University, Wistar Institute and The Walter Reed Institute for Research, working on autoimmunity, immunity to cancer, and vaccines to infectious agents. Brando's research focuses on the generation of cell-based and ligand binding assays to assess the cellular and humoral immune response to vaccines and therapeutics. Brando has developed various novel flow-cytometry, Elispots and Elisa assays to investigate T and B cell response.

Ryan Breen

Managing Director, Audit,
KPMG LLP

Ryan is a Managing Director in KPMG's Audit practice in Philadelphia. He has more than 14 years of experience providing financial statement audits and audits of internal controls. Ryan has worked on a variety of clients in Pharmaceuticals, Life Sciences and Technology industries and also has experience on larger industrial companies including both public and private sectors. Ryan has experience working on successful IPOs for multiple clients in the biopharma industry and has contributed on additional IPO engagements

from both a project management and quality review perspective. Ryan has vast experience with audits of Internal Controls over Financial Reporting and has experience advising clients on their early development and implementation of their control environment. Ryan has experience auditing the following areas: initial public offerings and comfort letters; Business Combinations; Internal Controls over Financial Reporting; Complex Debt and Equity Transactions; Revenue Recognition in accordance with ASC 606; Leases in accordance with ASC 842; Equity method of accounting; Inventory; Stock-based Compensation; Income Taxes; and Consolidation and Group reporting.

Philip J. (P.J.) Brooks

Acting Director, Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences
National Institutes of Health

Philip J. (P.J.) Brooks is the acting director of NCATS' Division of Rare Diseases Research Innovation. Brooks received his doctorate in neurobiology from The University of North Carolina at Chapel Hill. After completing a postdoctoral fellowship at The Rockefeller University, he became an investigator in the intramural program conducted by the National Institute on Alcohol Abuse and Alcoholism. He developed an internationally recognized research program focused on two distinct areas: the molecular basis of alcohol-related cancer; and rare neurologic diseases resulting from defective DNA repair, including xeroderma pigmentosum, Cockayne syndrome and Fanconi anemia. Prior to his tenure in the division, he worked in NCATS' Division of Clinical Innovation, where he was the lead program director for the Clinical and Translational Science Awards (CTSA) Program Collaborative Innovation Awards, designed to fund projects that will result in novel and creative approaches to overcoming roadblocks in translational science (PAR-18-244 and PAR-18-245). Brooks represents NCATS in the NIH-wide Gene Therapy Working Group and on the Regenerative Medicine Innovation Project. He also is the working group coordinator for the NIH Common Fund program on Somatic Cell Genome Editing and is one of the leaders of the PaVe-GT and Bespoke Gene Therapy consortium.

R. Carter Caldwell, M.B.A.

Penn Medicine Co-Investment Program Director
University of Pennsylvania

As the Penn Medicine Co-Investment Program Director, Carter leads Penn Medicine's investments in the cell therapy, gene therapy, and connected health sectors. Utilizing multiple decades of experience as both an entrepreneur and an investor, he sources investment opportunities, manages relationships with co-investors, completes investment rounds, and supports the governance of the funded companies. Carter was previously a Managing Director with Cross Atlantic Capital Partners, a venture capital firm with 4 funds and over $500 million under management. He has a strong technology background, having founded and managed two software companies. Carter holds an MBA from Columbia University and a BA in Philosophy, Politics and Economics from the University of Pennsylvania.

Rui Che

Managing Director, Tax,
KPMG LLP.

Rui is a Managing Director in KPMG's Economic and Valuation Services practice based in the Philadelphia office, with over 15 years of experience in transfer pricing. Her clients include leading multinational firms in the pharmaceutical, chemicals, telecommunication, and consumer products industries, with a focus on life science (biopharmaceutical and medical devices) clients. Rui serves as a co-industry lead for KPMG's transfer pricing team in the U.S. Rui has extensive experience with global business / tax restructuring, transfer of intangible property, and value chain analyses for multinationals. Her experience covers the entire spectrum of transfer pricing: planning, documentation, and audit defense. With respect to the life sciences industry, she has served as a long-term consultant for several major pharmaceutical companies. In addition, she has helped multiple biopharmaceutical start-ups and mid-market companies with their tax structure and transfer pricing compliance obligations. Recently she worked with several companies that focus on cell and/or gene therapies to assess their value chains and design optimal tax structure.

Gong Chen, Ph.D.

Co-founder; Chief Scientific Officer
NeuExcell Therapeutics

Gong Chen graduated from Fudan University and obtained his PhD degree in Shanghai Institute of Physiology. Dr. Chen did postdoctoral work at Yale University and Stanford University before joining the faculty of Penn State University, where he was a Professor and Verne M. Willaman Chair in Life Sciences till 2019. Since January 2020, Dr. Chen joined Jinan University in Guangzhou, China to lead a Brain Repair Center focusing on translational research by developing neuroregenerative gene therapy to treat neurodegenerative disorders. Dr. Chen pioneered an innovative *in vivo* reprogramming technology, converting reactive glial cells directly into functional neurons *in situ*. Dr. Chen and his team published a series of articles on NeuroD1-based gene therapy, laying solid foundation for a potential disruptive therapy using internal glial cells to regenerate functional new neurons for neural repair. Dr. Chen also developed a chemical reprogramming technology, using a cocktail of small molecules to convert human glial cells into

functional neurons, paving the way for a potential drug therapy for neural regeneration and repair. Dr. Chen published many research articles in world leading journals including Cell Stem Cell, Nature Communications, Neuron, PNAS, and received the Zenith Fellows Award from Alzheimer's Association. Dr. Chen organized and Chaired the first symposium on *in vivo* reprogramming at the 2014 annual meeting of the Society for Neuroscience in Washington DC, marking a new horizon for neural regeneration and repair. Dr. Chen has 160 patent applications with 40 patents issued world-wide.

Tim Conrey
SVP
Scheer Partners

Paul 'Tim' Conrey is a Philadelphia veteran local commercial broker and a former medical researcher specializing in meeting the unique needs of the area's biotechnology businesses. He holds a M.S. degree in organic chemistry from George Washington University, and over his 30-year career has brokered numerous signature transactions in the Philadelphia area, said joining Scheer Partners is a "great opportunity to work with a team of exceptionally talented professionals who recognize the opportunity to help meet the unmet scientific real estate needs of the incredible and rapidly developing life sciences industry in the Philadelphia market." The announcement of Scheer's first satellite office – located in CIRA Centre, 2929 Arch Street, Philadelphia, PA. He added, "Over the past few years my work – including involvement in construction of a transformative, multi-function research/headquarters space in the Curtis Center – on behalf of Philadelphia's Imvax, Inc. (www.imvax.com), the promising immunotherapy vaccine developer, fueled my passion to focus full time on this sector. There's no better fit for me, or life sciences businesses with real estate needs, than Scheer."

Xiao-ping Dai, Ph.D.
Senior Vice President & Chief Technology Officer
IVERIC Bio

Dr. Dai has more than 20 years of experience in the biopharmaceutical industry, specialized in product and process development and manufacturing. She has successfully developed processes and managed overall CMC development for more than 30 different pharmaceutical products including oligonucleotide, monoclonal antibodies, fusion proteins, pegylated proteins, ADCs, multi-specific antibodies, vaccines, gene therapies and small molecules, from preclinical development through commercialization, including Opdivo, Yervoy and Reblozyl. Dr. Dai has a proven track record of internal and external development, with CDMOs/CMOs, managing multiple partnerships and collaborations, technology transfers, scale-ups, process performance qualifications (PPQ) and regulatory filings. Prior to joining Iveric Bio, Dr. Dai was Chief Technologist and VP of Process and Technology Development at WuXi Advanced Therapy, a CDMO where she built and led an organization engaged in process and technology platform development, serving cell and gene therapy clients. Prior to joining WuXi, Dr. Dai was Sr. Director of Biologics Development and Manufacturing at Celgene Corporation, where she built and led a strong technical team and successfully delivered on multiple internal and external programs. Prior to Celgene, Dr. Dai had over 13 years of effective functional and cross-functional leadership and technical experience in Biologics Development at BMS, Medarex and Regeneron Pharmaceuticals, and before that at NJIT, where she received her Ph.D. in Chemical Engineering.

Tom Dalfo
Sr. Vice President
Real Estate Services of Philadelphia Industrial Development Corporation

Tom Dalfo is Sr. Vice President, Real Estate Services of PIDC, a public- private partnership between the City of Philadelphia and the Greater Philadelphia Chamber of Commerce focused on attracting investment to spur equitable development throughout Philadelphia. Tom manages the acquisition and sale of publicly owned industrial land and has completed 200+ land transactions in Philadelphia during his tenure. He joined PIDC as part of a team that acquired military facilities closed in the 1990s, most notably the Navy Yard.
Tom's team at PIDC has been at the heart of Philadelphia's planning for the city's industrial sector. Over the past decade, Tom's group has managed the Philadelphia Industrial Land & Market Strategy and the Lower Schuylkill Master Plan. The latter which has guided PIDC's efforts to reposition vacant and contaminated riverfront sites in Southwest Philadelphia into a modern campus capable of supporting 1 million square feet of bioprocessing facilities. Prior to PIDC, Tom was the Director of Economic Development for the Philadelphia Water Department. He also worked for the Cooper's Ferry Development Association managing the Camden waterfront redevelopment. Tom has degrees from La Salle University and the University of Pennsylvania and is a Roxborough resident.

Hien Dang, Ph.D.
Chief of the Division of Surgical Research in the Department of Surgery and Assistant Professor
Thomas Jefferson University

Dr. Dang is the Chief of the Division of Surgical Research in the Department of Surgery and Assistant Professor at Thomas Jefferson University at the Sidney Kimmel Cancer Center in Philadelphia, PA. Her lab studies the oncogenic roles of RNA binding proteins in primary liver cancer using genomics, bioinformatics, translational science, molecular biology, CRISPR/Cas9 tools and RNA biology. In addition to bench science, her team is currently collaborating with medical

oncologists and surgeons to develop biomarkers to identify patients at high risk of HCC.
Dr. Dang has a B.Sc. in Bioinformatics and did her postdoctoral fellowship at the National Cancer Institute, Bethesda, MD. There she studied the roles of RNA binding proteins in cancer. Dr. Dang received The NCI's Director's Innovation Award, NIH/NCI's APSAA 2017 Young Investigator Award, and the NIH/NCI Director's Award of Merit for her scientific work. She is the 2019 American Liver Foundation Charles Trey MD Memorial Liver Scholar and was awarded the American Cancer Society-Internal Research Grant, the American Gastroenterology Association Pilot Award, WWSmith Charitable Trust Award, and the Charles Hevner Scholar's Award.

Chris Dokomajilar

Founder and CEO
DealForma, LLC

Chris Dokomajilar is the founder and CEO of DealForma, the life science-focused database and custom analytics service providing deal benchmarking for the biopharma industry. Prior to founding DealForma, Chris held research, management consulting, and industry analytics roles within biopharma and academia at Recap, Deloitte, Thomson Reuters, BioCentury, and the University of California San Francisco. He enjoys the opportunity to contribute to industry thought-leadership and is frequently invited to speak to industry groups about biopharma business development, licensing, and finance. Chris holds molecular biology degrees from the University of California Berkeley.

Andreas Dreps, Ph.D.

SVP Oncology Drug Development Services
ICON Clinical Research

SVP and Global Head of Oncology Drug Development Services at ICON Clinical Research. Andreas has expertise in Phase I-III clinical development of chemotherapies, molecular targeted therapies, tumor vaccines and immuno-oncology drugs and CGT involved in the submission of 30+ INDs. Dr. Dreps has worked extensively in both haematological malignancies as well as solid tumors and has development experience with multiple mechanisms and modalities from chemotherapy through to CAR-T.

Ding Ding, Ph.D., M.B.A

Former head of APAC Healthcare Investment Banking and Capital Markets
Credit Suisse

Ding Ding, Ph.D. is the founder and chairwoman of Augere Group, which focus on providing corporate finance advisory and investment services for healthcare companies globally. Dr. Ding had 20 years of healthcare investment banking and equity research experience in New York, Hong Kong and China with leading global banks and served as the CFO of a leading pre-IPO stage biotech company in the US. Dr. Ding was most recently the head of APAC Healthcare Investment Banking and Capital Markets at Credit Suisse, and the head of China healthcare investment banking at Barclays and Nomura respectively prior to joining Credit Suisse. Dr. Ding and her team advised some of the most important landmark IPOs, private capital raise and M&A transactions across all healthcare subsectors over the past decade, including 3 out of the 4 largest life science IPOs out of Asia (Beigene, Zai Lab, Everest), largest cancer genomic IPO on Nasdaq (Genetron), 1st chapter 18A medtech IPO in Hong Kong (Venus Medtech), largest healthcare SPAC/de SPAC out of Asia (New Frontier/Chindex), 2 largest private capital raise for Healthcare companies out of Asia (Ruipeng, WeDoctor), and some of the largest cross-boarder healthcare M&A transactions to date, including Stryker's acquisition of Trauson and Luye's acquisition of Healthe. Dr. Ding received her Ph.D. in pharmacology/neuroscience from State University of New York, Downstate Medical Center, and her MBA in finance from the Wharton School, University of Pennsylvania.

Eva Essig, Ph.D.

Independent Regulatory Consultant

Eva Essig, PhD, is a dedicated leader with over 30 years of regulatory affairs experience with innovative drugs, biologics, biosimilars and most recently in gene therapies utilizing CRISPR/Cas9 genome editing and AAV technology. Most recently, Dr. Essig was Senior VP of Regulatory Affairs at Jaguar Gene Therapy. Prior to joining Jaguar Gene Therapy, Dr. Essig built and led the Regulatory Affairs and Quality functions at Intellia Therapeutics, where she set the global regulatory strategy for initiation of the first in vivo CRISPR/Cas9 clinical trial for treatment of transthyretin amyloidosis followed by the second in vivo program for hereditary angioedema and autologous cell-based gene therapy for AML. With extensive expertise in global pharmaceutical regulations, Dr. Essig has developed and implemented regulatory strategies in novel settings across multiple therapeutic areas. She has served in regulatory affairs positions of increasing responsibility at Searle/Pharmacia/Pfizer, Northfield Laboratories, Astellas Pharma, Hospira/Pfizer, with successful global approvals of

multiple products. She holds a BSc in neurobiology from McGill University (Montreal, Canada) and PhD in neuropharmacology from University of Bristol (Bristol, UK).

Chaohong Fan, M.D., Ph.D.

Team Leader and Acting Branch Chief at the Malignant Hematology Branch
Food and Drug Administration

Dr. Fan is a lead oncology medical officer with 17 years of experience at the Center of Biologics Evaluation and Research (CBER) and the Center of Drug Evaluation and Research (CDER) in the U.S. Food and Drug Administration (FDA). Dr. Fan serves as a team leader at the oncology branch and as an acting branch chief at the Malignant Hematology Branch at the Office of Tissues and Advanced Therapies (OTAT), CBER. OTAT facilitates the development and approval of the most innovative cancer therapeutics with curative potential. These therapeutics include chimeric antigen receptor (CAR) T cells, adoptive T cell therapies, tumor neoantigen-based personalized immunotherapies, oncolytic viruses, and combinations of cellular and gene therapies with other immunologic agents such as checkpoint inhibitors. Dr. Fan is a medical oncologist certified by the American Board of Internal Medicine (ABIM). She received an M.D. from Zunyi Medical College, and a M.Sc. in medical genetics from Hunan Medical University, China. She also holds a Ph.D. in medical genetics from Umea University in Sweden. Prior to joining the FDA, Dr. Fan conducted post-doctoral research in gene mapping and cloning for neurogenetic disorders, including Amyotrophic Lateral Sclerosis (ALS), at Northwestern University in Chicago, USA. Her regulatory expertise focuses on clinical trial design and development of gene and cellular therapies and precision medicine in oncology.

Joseph Fetterman, M.B.A.

Executive Vice President, Healthcare Services
Colliers International

Joe leads the Life Sciences and Healthcare real estate practice in the Philadelphia region for Colliers, a global real estate services company. He specializes in providing strategic real estate solutions for Life Science clients in a complex, competitive environment. Working with research institutions, start-ups and growing drug development companies at all stages of maturity, Joe has developed an understanding of the challenges facing growing life sciences companies and assists them in establishing an effective real estate occupancy strategy to address future uncertainties related to the advancement of the science, success in pre-clinical and clinical stages, raising and utilization of capital and recruitment of talent. In addition to working with Life Sciences companies, Joe's team advises and represents building owners who are developing or converting projects specifically focused on R&D lab and cGMP manufacturing. Colliers is currently representing Budd Bioworks at Wissahickon and Hunting Park Avenues and assisting PIDC in selecting a developer for the 40 acre Lower Schuylkill Biotech Campus. Joe received a BARCH from Drexel University and an MBA from The Wharton School. He has been involved with the design, construction, development, leasing and sale of projects totaling over 5 million square feet. Joe is co-chair of ULI Philadelphia's Health & Life Sciences Council and a member of Life Sciences PA.

Audrey Greenberg

Co-Founder and Chief Business Officer
Center for Breakthrough Medicines

Selected as one of the Top Trailblazers in Biotech, Audrey Greenberg has a strong track record of building highly successful life science companies through capital attraction, strategic relationships, novel technologies, and top-tier management teams. She is Co- founder of the Center for Breakthrough Medicines and Discovery Labs, a Cellicon Valley-based ecosystem for streamlining the path to commercialization for cell and gene therapies. CBM is a Cell and Gene therapy focused CDMO offering a comprehensive development, manufacturing and testing solution for advanced therapies. Audrey serves as Chief Business Officer for CBM and is responsible for business development, strategic direction, team attraction, and acquisitions. Before launching CBM, Audrey working in private equity as a senior executive at a $100+ billion fund manager. She also spent time on Wall Street as an investment banker at Morgan Stanley where she focused on Mergers and Acquisitions and Capital Raises in the technology sector. Audrey started her career at Deloitte and has an MBA from the Wharton School. Audrey serves on the board of directors for publicly-traded NYMT as well as the King of Prussia Business District and Greater Philadelphia Chamber of Commerce.

Claire Greenwood

Executive Director, CEO Council Growth

As the Senior Vice President of Economic Competitiveness, Claire Greenwood is responsible for advancing the work of the Chamber designed to attract and expand companies, capital, and talent in the Greater Philadelphia region. She and her team engage C-Suite leaders from Chamber members and investors in these efforts to build on and amplify the region's competitive advantages and accelerate equitable economic growth. They drive the work of two Action Teams (Health Care and Life Sciences and Energy), a multi-platform approach to the region's talent and workforce challenges, and the organization's

partnerships and efforts to ensure companies Select Greater Philadelphia. Ms. Greenwood also serves as the Executive Director of the Chamber's regional CEO Council for Growth, a committed group of nearly 60 business, higher education and civic leaders working to make Greater Philadelphia one of the global first-tier 21st-century innovation economies. Ms. Greenwood graduated from the University of Delaware with a BA in Biological Sciences and a minor in psychology and holds a Master's of Science in Organizational Dynamics from the University of Pennsylvania. Ms. Greenwood is a member of the Board of Directors for Campus Philly and the United Way of Greater Philadelphia and Southern New Jersey.



Dennis M. Gross, MS, PhD, SSYB, SFC

Chief Executive Officer
Pennsylvania Drug Discovery Institute

Dennis M Gross, MS, PhD is the CEO for the Pennsylvania Drug Discovery Institute. He is also teaching faculty in the Jefferson College of Life Sciences and Adjunct Associate Professor of Pharmacology & Experimental Therapeutics in the Sidney Kimmel Medical College of Thomas Jefferson University (TJU). In addition, he is Corporate Faculty at Harrisburg University of Science & Technology. Previously, he was the Associate Dean at TJU for Program Development and Assessment and Director for the Professional Science Masters Programs. Prior to this, he was at the Merck Research Labs for 29 years retiring in 2006 as Senior Director and Head of Business Operations with overall responsibilities for capital planning and facilities in Pennsylvania, California, and Massachusetts. He was also responsible for lab projects and operations oversight at MRL sites in Canada, Japan, Italy, and the UK. In his Merck career he held several positions ranging from bench scientist to M&A activities and liaison for basic research and clinical drug development in Japan working with Banyu Pharmaceuticals. During his tenure at Merck, he also served as Adjunct Professor of Global Logistics in the School of Business and Industry of Florida A&M University. He has worked with the CSIS Studies on policy issues relating to biological weapons of mass destruction.

He received his BA and MS from California State University and his PhD from UCLA pursuing a postdoctoral fellowship in pharmacology at the Tulane University School of Medicine. He has also participated in executive education programs at Wharton, MIT and the Tufts School of Law and received NIMS and ICS certification from FEMA. He serves as the National Co-Chair for the Biotechnology Entrepreneur Bootcamp. He is a member of the American Association for Pharmaceutical Scientists, American Chemical Society, History of Science Society, International Society for Pharmaceutical Engineering, Sigma Xi and SAPA-GP.

Mahen Gundecha, M.B.A.

Chief Business Officer
Exegenesis Bio

Mahen Gundecha leads corporate strategy, global business development and corporate communications for Exegenesis Bio. Mahen also leads the formation of strategic partnerships across all areas of our business, including R&D, manufacturing and commercialization. Mahen brings a depth of strategic, commercial and operational experience in biotechnology and cell and gene therapy to Exegenesis Bio, with previous leadership experience at Novo Nordisk, Novartis/Sandoz, Juno Therapeutics and emerging biotechnology and cell and gene therapy companies. Mahen has led business development transactions in neurosciences, oncology and rare diseases, has managed large-scale strategic partnerships in cell and gene therapy and has guided corporate strategy for emerging biotechnology companies. Mahen Gundecha and his team are responsible for licensing and acquiring innovative technologies to support our development and manufacturing activities, identifying novel clinical programs to enhance our pipeline and forming strategic partnerships to accelerate our growth.
Mahen holds BSc (Biology), BSc (Finance) and MBA (International Business) degrees from leading global universities.

Weinong Guo, M.D., Ph.D., FACC

Senior Vice President, Clinical Research
Alnylam Pharmaceuticals Inc.

Dr. Weinong Guo joined Alnylam in May 2021 as Senior Vice President of Clinical Research. In this role, he leads the Clinical Research team and oversees the clinical development programs in CardioMetabolic and Prevalent Disease area, including Zilebesiran (formerly known as ALN-AGT), Lumasiran, ALN-HSD, and ALN-XDH, etc.
Before joining Alnylam, Dr. Guo worked in CardioRenalMetabolic Development Unit in Novartis for about 14 years where he played a key role in a number of high-priority clinical development programs including successful registration and life cycle management of EntrestoÒ (sacubitril/valsartan) for chronic heart failure, hypertension and myocardial infarction. Dr. Guo spent 20 years in the industry including Solvay and Schering-Plough during his early career.
Dr. Guo received his MD degree from Soochow University in China and his PhD from Nagoya University in Japan. He completed his cardiology training at 2nd Affiliated Hospital at Soochow University, and an AHA postdoctoral fellowship in cardiac electrophysiology and pharmacology at Washington University in St. Louis before joining the industry. Dr. Guo has been a Fellow of American College of Cardiology since 2005.



Xianxin Hua, M.D., Ph.D

Professor of Cancer Biology
University of Pennsylvania

Xianxin Hua, M.D., Ph.D., Professor of Cancer Biology, Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine. Dr. Hua has a long-term interest in investigating how the Menin epigenetic pathway regulates gastrointestinal (GI) cancers including neuroendocrine tumors (NETs) as well as acute myeloid leukemia (AML), and in developing innovative chimeric antigen receptor (CAR)-expressing T cell therapies. Although CAR-T therapy has achieved remarkable success in treating B cell lineage-related leukemia, the progress is lagging for treating solid cancers. Dr. Hua's team invented the STAR technology platform to quickly identify multiple antibodies targeting tumor associating antigens (TAAs) for solid cancers. His group developed novel CAR T therapy for treating the aggressive GI-cancers, and recently discovered that CDH17CART cells eradicated multi-types of solid cancers, including NETs, gastric and colorectal cancers, and pancreatic cancers in preclinical models. Notably, CDH17CARTs do not cause toxicity to healthy normal cells that also express CDH17 protein. These studies pave the way to develop novel immunotherapy to treat the aggressive solid cancers. Dr. Hua's research led to multiple patents including CDH17CART technology licensed to Chimeric Therapeutics by Penn. He has also involved in startups and consulting for biotech companies, and published over 100 peer-reviewed papers in journals including Nature, Cell, and Nature Cancer.

Jingjun (Jim) Huang, Ph.D.

CEO
Ascendia Pharmaceuticals

Dr. Jim Huang founded Ascendia in 2012 after a career in pharmaceutical R&D and management at Pfizer, Baxter, AstraZeneca, and most recently Roche. He has led the formulation development efforts for the successful transition of several oral and parenteral dosage forms from discovery through formulation, manufacturing, technical transfer and ultimately commercialization. Dr. Huang holds a Ph.D. in Pharmaceutics from the University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy and Sciences) where he worked with Joseph B. Schwartz. Dr. Huang's research interests are centered on improvement of solubility and dissolution for, and controlled delivery of, poorly water soluble drugs through nano-emulsion, nano-particle and amorphous solid dispersion technologies. His publications include studies on drug solubilization and controlled delivery in polymeric solid dispersion systems, amorphous drug delivery systems, controlled release, modeling and simulation, thermal and spectroscopic characterization of amorphous molecular dispersions, drug-polymer interactions and its significance on physical stability of amorphous drug, and micro/nano particulates for use in parenteral dosage forms. He has been a reviewer for the Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, Journal of Controlled Release, Drug Development and Industrial Pharmacy, PDA Journal of Pharmaceutical Science and Technology, Molecular Pharmaceutics, and Pharmaceutical Research. Currently, he is a member of American Association of Pharmaceutical Scientists (AAPS) and American Chemical Society (ACS).

Stephen Hughes, Ph.D.

Director of New Platform Development
Genscript

Stephen Hughes is Director of New Platform Development at GenScript, responsible for next-generation synthetic DNA production systems for gene therapy. He has negotiated optimum quotes from suppliers for a core system for scaled production of dsDNA, ssDNA, and IVT template DNA without plasmid, bacteria, or yeast for CAR-T, TCR-T, AAV, and lentiviral gene therapy. Previously at Spark Therapeutics he provided the overall strategic and tactical leadership for the establishment and implementation of automation and robotics associated with optimizing operations and compliance for preclinical development, manufacturing, and testing. He was responsible for designing the automation strategy to enable new hardware technology development and implementation to scale for automation of preclinical development, manufacturing, and testing capabilities across all therapeutic areas for Spark. He held increasingly responsible positions at USDA where he supervised a laboratory to support high-throughput gene optimization and functional proteomic operations. He designed and built an integrated robotic platform to perform high-throughput gene assembly, cloning, transformation, expression, and assay operations for screening mutagenized genes and synthetic chromosomes to use in improving functions of industrial microbial strains. He has also held positions in pharmaceutical and biotechnology operations at Cell Pathways, Worthington Biochemical Corp., Hudson Robotics, and Quality Biotech in synthetic genomics, protein expression, fermentation processes, robotic platform design, and quality control of biologics. While a post-doctoral fellow in the Neuroscience Department at Hoechst Marion Roussel, Inc., he engineered a novel two-hybrid technology to identify protein-protein interactions involving the plaque-forming Aβ peptide implicated in Alzheimer's disease. He holds an undergraduate degree in Biology specializing in Genetics and a PhD degree in Molecular Genetics, Biochemistry, and Microbiology. Steve has spent his career conducting research in all aspects of molecular biology and automation and is recognized as an expert in the areas of heterologous protein expression, gene optimization, design of integrated robotic platforms for automated molecular biology routines, and improvement of industrial microbes and cells. He has been invited to give more than 34 international and national presentations. He is first author on 18 peer-reviewed journal articles, has authored or co-authored 10 book chapters on automated molecular biology and

biofuels, and is listed as inventor on 4 patents. He is on the editorial board of 4 journals, has organized 5 CRADAs, including 1 international, and participates in review panels for the Department of Energy, Advanced Research Projects Agency – Energy, the National Science Foundation, the Center for Biorenewable Chemicals, and the USDA. 13.Elected Chairman of Illinois Heartland Section of the American Chemical Society, 2006. (Section received Chem Luminary Award for 2006, highest honor section can win)

Vibha Jawa, Ph.D.

Executive Director
Bristol Myers Squibb

Dr. Vibha Jawa is an Executive Director for Biotherapeutics Bioanalysis in Nonclinical Disposition and Bioanalysis (NDB) organization at Bristol Myers Squibb. Vibha is responsible for leading biotherapeutic and cell /gene therapy bioanalytical (BA) function supporting DMPK and immunogenicity, and providing strategic and scientific oversight for BMS developmental portfolio. Vibha was at Merck for 4 years where she led the Predictive and Clinical Immunogenicity group and at Amgen for 14 years supporting Discovery to Development for biotherapeutics. Vibha has 20+ years of experience in diverse fields of biologics, vaccine development and gene therapy with successful support of 20 + IND, BLA and MAA filings. Vibha is a recognized leader in Bioanalysis and Immunogenicity with 75+ peer-reviewed publications and serves as a Reviewer and Editor for The AAPS Journal and J. Pharm Sci. She is an active member of multiple scientific societies and consortiums (IQ, SC space Consortium and EIP). Within AAPS, she is Steering Committee member of the Therapeutic Product Immunogenicity Community, past chair of Immunogenicity Risk Assessment and Mitigation Community and leads the IQ Consortium for Cell/Viral/Gene therapies. Vibha enjoys volunteering as a board member for the state youth orchestra and mentoring high school students on STEM related projects in her free time.

Guodong (Javier) Jia, Ph.D.

Chief Executive Officer
OBiO Technology (Shanghai) Corp., Ltd

CEO in OBiO Technology (Shanghai) Corp., Ltd. (stock code 688238), is dedicated to Gene and cell therapy CRO/CDMO/CMO service, from lab scale CRO, Non-IND manufacturing, IND-CMC service, and GMP manufacturing for clinical trials and commercialization. The technical team at OBiO has more than 10 years biopharma industry experience, and has completed more than 100 gene therapy projects, covering plasmid, AAV, Lentivirus, and different oncology viruses, mRNA vaccine, CAR-T, CAR-NK and Stem Cell in past 5 years. Specially, some projects already be approved in US. Most recently, Dr. Jia is leading the 77,000m2 facility GMP site construction for future commercialized GCT CMO. Before OBiO, he led a technical team in GE Healthcare Life Sciences (Cytiva) to provide IND service to biopharma companies, including cell culture and purification process development, assay development and qualification, tech transfer, scale up to tox run manufacturing to support CTA in China. Built GE China two biomanufacturing pilot platforms for MAB IND, which has been passed CFDA on-site inspection for CTA. Complete more than 90 process development projects on vaccine, plasma, MABs, R-proteins, Biochemicals, and transfer these project to different companies. Expert on single use technology, process validation, DoE, QbD, HTPD, project management. Published 8 SCI papers, co-editor for 2 CFDA regulatory handbooks, Vice editor for <Cell Therapy> , Biopharma chairman in ISPE China committee. Ph.D degree on biochemical engineering, downstream purification background.

William Jia, Ph.D.

Chief Scientific Officer, Co-Founder
Virogin Biotech

Dr. Jia was previously the PI and head of a laboratory specialized in Gene Therapy and Virus Vector in the Centre for Brain Health at the University of British Columbia (UBC). As an active academic, he was also a tenured associate professor in UBC's Faculty of Medicine, and an associate member of British Columbia's Cancer Centre. He has published more than 120 papers in international journals, invited to publish 90 academic reports and abstracts, and owns over 10 patents. With over 20 years of experience in R&D, management and entrepreneurship, Dr. Jia is among the world's pioneers in oncolytic virotherapy and immuno-oncology. For his work and dedicated efforts in the field, Dr. Jia was among the Best Medical Scientists in Canada on Time Magazine's (Canada) in August 1999. In 2015, Dr.Jia co-founded Virogin Biotech Ltd in Vancouver, Canada with his partners. Virogin has raised more than $300m USD investment since then. Its first OV product (VG161) is in Phase II clinical trials in China and US and the next gen OV (VG201) has also entered Phase I in both countries.

Man-Shiow Jiang, Ph.D.

Executive Director, Viral Vector, Cell MFG-PD
Wuxi Advanced Therapies

Man-Shiow Jiang received MS degree in Biochemistry in National Taiwan University, school of medicine in Taiwan, ROC. She had worked in the department of Rheumatic and immunology at Taichung Veteran Hospital for four years prior

to pursue her PhD degree in Biochemistry, Cellular and Molecular Biology (BCMB) graduate program in the Johns Hopkins University (JHU), school of medicine in Baltimore, MD. Later, she spent five-year as postdoctoral fellow in the Department of Biological Chemistry at JHU. Most of her career is in CDMO including private companies (Omnia and Vigene) and government contractors (NCI-SAIC and NIH-VPPL). She is currently leading the department of VVPTD, Cell and Gene Therapy at WuXiAppTec. Man-Shiow has over 22 years of bioprocess experiences in cell and gene therapy including the development and production of protein, antibody, cytokines, fusion protein, and viral vectors. Her professional interests focus on the optimization/streamline of the process development for viral vectors from R&D to commercialization.

Frederick "Rick" Jones, M.D., M.B.A.

Partner
BioAdvance

Frederick “Rick” Jones, M.D., M.B.A. is a Partner at BioAdvance, a Philadelphia-based early stage biotech venture capital firm. Dr. Jones has spent over 30 years in life science industries, serving as a physician, executive, consultant, director and investor. At BioAdvance he is responsible for investments in therapeutics and medical devices.
Previously Dr. Jones was a Director at Broadview Ventures, a Boston-based philanthropic venture fund focused on breakthrough technologies in cardiovascular disease. Prior to Broadview Dr. Jones served as CEO of Anchor Therapeutics, a venture-backed company, which was developing a platform based on peptide modulators of GPCRs. Prior to Anchor, Dr. Jones held executive positions with Devgen NV (Ghent, Belgium) and BioRexis (acquired by Pfizer). Dr. Jones began his industry career at Wyeth Pharmaceuticals, initially in Global Medical Affairs and subsequently in Global Business Development. Dr. Jones is a board-certified internal medicine physician who practiced in the US Navy, the Lahey Clinic (Burlington, MA) and at the University of Pennsylvania. He received his BA, MD and MBA degrees from the University of Pennsylvania.

Bin Hu Karg,, J.D.

Partner
VCL Law

Bin Hu Karg is a founding partner of VCL Law LLP. Her practice focuses on representing technology, life sciences and growth business enterprises at all stages of development, from inception into fund raising and eventually exiting through IPOs or M&A. Her areas of expertise include venture financings, equity and debt private placements, public offerings, corporate governance, SEC compliance, joint ventures, mergers and acquisitions, licensing and technology transactions and other corporate and securities law matters. Ms. Karg has a decade of experience in both private and public financings and in advising enterprises as well as investors. She started her legal career at Davis Polk & Wardwell LLP where she represented corporate and financial institution clients across a broad range of capital markets transactions, including IPOs and other equity offerings, and investment-grade, high-yield and convertible debt offerings. She later joined Wilson Sonsini Goodrich & Rosati, P.C. where she advised emerging growth companies and public companies on venture financings, private equity transactions and SEC registered offerings. Ms. Karg is also recognized for her extensive experience in cross-border transactions. Having counseled buyers and investors in investments and acquisitions in Asia and Europe, Ms. Karg is well positioned to be a trusted advisor to her clients in carrying out their global strategies. Ms. Karg earned a J.D. from Columbia Law School, an L.L.M. from New York University School of Law, and an L.L.B. from Beijing Foreign Studies University School of Law. Ms. Karg is admitted to practice law in New York and Texas.

Louis P. Kassa III, M.P.A.

Executive Vice President; Chief Operating Officer
Pennsylvania Biotechnology Center of Bucks County

Louis P. Kassa III has been Chief Operating Officer of The Pennsylvania Biotechnology Center, Baruch S. Blumberg Institute and Hepatitis B Foundation since December 2014. Kassa oversees daily operations, finance, business development, and compliance at the Pennsylvania Biotech Center (PABC), which is home to the Hepatitis B Foundation and its research entity, the Baruch S. Blumberg Institute. In 2017, Kassa was promoted to Executive Vice President/Chief Operating Officer. In 2020, Kassa was named one of “The 10 Best COOs of 2020” by Industry Era, a global technology media outlet. From 2015 to 2017, Kassa worked part-time as the Chief Executive Officer for Youth Services Agency, a non-profit social services agency. In 2017, Kassa co-founded Family Foundations Partnership and is currently the Chief Executive Officer. He previously served as State Director and Chief Operating Officer at VisionQuest National Ltd., a national behavioral health company. Kassa received his undergraduate degree from Penn State University and received a Master in Public Administration from Villanova University in December 2007.

Emily Kramer-Golinkoff

Co-founder
Emily's Entourage

Emily Kramer-Golinkoff is Co-Founder of Emily's Entourage, a 501(c)3 that accelerates research for new treatments and a cure for nonsense mutations of cystic fibrosis. She is also a patient advocate and speaker. Since 2011, Emily’s Entourage has awarded millions of dollars in research grants, launched a

CF gene therapy company, developed a patient registry and clinical trial matchmaking program to accelerate clinical trial recruitment, and led worldwide efforts to drive high-impact research and drug development. Emily has a master's degree in bioethics and certification in clinical ethics mediation from the University of Pennsylvania, where she also completed her undergraduate degree. She was named a "Champion of Change" for President Obama's Precision Medicine Initiative and is the recipient of the 2020 Philadelphia Magazine Luminary Award and 2016 Global Genes Rare Champion of Hope for Advocacy Award.

Patrick J. Kelly, Ph.D., J.D.

Counsel
Stradley Ronon

Pat began his career as an academic scientist at the Georgia Institute of Technology where he earned his Ph.D. in molecular biology. He has expertise in biochemistry, immunology, virology, proteomics, genomics, transgenic animals, gene therapy and drug delivery systems. Prior to joining Stradley Ronon, Pat was a partner in patent and general practice law firms, and served as an advisor to start-up programs and medical technology incubators.

In addition to his practice as external patent counsel, Pat has served as on-site patent counsel for his clients. In particular, a biotech/pharmaceutical company where he served as acting director of intellectual property. He was responsible for a wide variety of patent matters, including review of invention disclosures, due diligence reviews, freedom-to-operate opinions and preparation and review of licensing agreements.

Pat also served as on-site patent counsel for the life sciences and chemical analysis division of a major scientific instrument company. His responsibilities included review of invention disclosures for filing decisions, patent application drafting and prosecution.

- J.D., *cum laude*, Temple University Beasley School of Law
- Ph.D., Georgia Institute of Technology
- M.S., University of Maryland, Baltimore County
- B.S., Georgetown University

James Li, M.D.

Co-Founder; Chief Executive Officer
JW Therapeutics

James Li, M.D. Co-founder, Chairman of the Board and CEO at JW TherapeuticsIn early 2016, James Li co-founded JW Therapeutics with Juno Therapeutics and WuXi AppTech, serving as Chairman of the Board and Chief Executive Officer.Prior to JW Therapeutics, James served as Vice President and the founding General Manager Greater China at Amgen, Partner at Kleiner Perkins Caufield & Byers life science practice, and several leadership positions across the US and Asia Pacific at Merck Co. & Inc.

Jessica Lee

Head, Clinical Science and Operations
Spirovant Sciences

Jessica has over 25 years of drug development experience, including Phase 1-3 clinical trial experience at Inovio, BMS, Merck and GSK. Throughout her career, Jessica has had increasing levels of responsibility and currently serves as Head, Clinical Sciences & Operations at Spirovant Sciences, Inc, where she has responsibilities for clinical development, operations and oversight of Spirovant's Cystic Fibrosis and respiratory disease product portfolio. She has worked across a variety of therapeutic areas, and she has managed complex drug/biologic/device programs in collaboration with industry, government, NGO, and academic partners. Jessica received her MPH from Drexel University Dornsife School of Public Health and her MS from Temple University School of Pharmacy.

Dongbei Li, Ph.D.

President
Accurant Biotech

Dr. Dongbei Li co-founded Accurant Biotech in 2017, a regulated (GxP and CLIA-certified) CRO providing PK/ADA/biomarker analysis for pre-clinical and clinical stages, using on a wide variety of analytical platforms including LBA, flow-cytometry, IHC/IF, qPCR, dPCR, LC/MS, etc. Dr. Li has extensive experience in dug development including bioanalysis, proteomics, toxicology, cell line development, clinical diagnosis and more. She served as a research scientist at Pfizer (La Jolla) and Amgen (Thousand Oaks). She returned to China in 2007 and started WuXi's large molecule bioanalysis operation. Under Dr. Li's leadership, the team grew significantly, passed all major regulatory inspection (FDA, OECD, EMA, CFDA), and supported the approval of several blockbuster biologics such as Cosentyx, Opdivo, Keytruda. Dr. Li received her B.S. in Biochemistry from Sun-Yet San University, M.S. in Biochemistry from Vanderbilt University and Ph.D. in Pharmaceutical Science from Fudan University.

Bo Liang, Ph.D., M.B.A.

Chief Executive Officer
iVIEW Therapeutics, Inc

Dr. Bo Liang is a serial entrepreneur with over 20 years' experience in drug discovery research, chemical and material sciences, biotechnology and materials venture and management. In 2006, Dr. Liang co-founded CLS Pharmaceuticals in New York City, where he invented a combination drug of Povidone Iodine and Dexamethasone, for the treatment of viral conjunctivitis. Within two years he has advanced the drug candidate into phase II trial, resulting in out-license to Foresight Biotherapeutics in 2008. From 2008-2010, Dr. Liang served as Executive Vice President, Pharmaceutical Development at Foresight to head the CMC development of the drug program for FST-100. After accomplishing phase II trials, the program was acquired by Shire Pharmaceuticals for $300m in 2015. Dr. Liang obtained his BSc. in chemistry from Peking University and PhD from the University of Pennsylvania, his MBA concentrating in entrepreneurship, and Finance from NYU Stern School of Business.

Fang Liu, J.D.

Partner
VCL Law

Ms. Fang Liu focuses her practice in the areas of corporate and securities law, with an emphasis on initial public offerings. She assists public and private companies in their corporate transactions including securitizations, public financings, banking, international market financings, cross-border acquisitions and other general matters. Ms. Liu has deep experience in advising China-based companies on going public in the U.S. and advising FINRA registered broker dealers on underwritten offerings. She is a frequent speaker on topics in connection with Chinese IPOs in the US and was interviewed by CCTV, Sina News and Caixin. She is also the co-author of widely publicized annual reports on the overview of Chinese IPOs in the US. Prior to co-founding VCL Law LLP, Fang was a partner at Mei & Mark LLP in Washington, DC. She also practiced securities law at Pillsbury Winthrop Shaw Pittman LLP and Loeb & Loeb LLP in Washington, DC. Ms. Liu earned a J.D. from Duke University School of Law, an M.A. from Beijing Foreign Studies University and a B.A. from Nankai University. Ms. Liu is admitted to practice law in Washington DC and Virginia.

Henry Lu, Ph.D., M.B.A.

Partner
NBS CAP

Dr. Lu is a partner of NBS CAP, focusing on M&A transactions in connection with public and private owned life science companies. Dr. Lu is also an angel investor and partner of NBS accelerator in Health care and deep technology industries. Dr. Lu is an active board member of several public companies: He was the Board Director of one of the largest China drug chain stores, listed in NYSE. He is also an Independent Director for both Hualian International (HK: 00969) and China Automotive Systems, Inc. (Nasdaq: CAAS). Dr. Lu was a Managing Director of China Merchant Capital, focusing on cross-border and investment restructuring opportunities in health care related industries. Before that, Dr. Lu is a Venture Partner of Sycamore Venture in New Jersey, a spinoff and strategic partner of Citibank Venture Capital platform. Dr. Lu was a Partner and the Head of China for William Blair & Company. He led the team managed 30+ public offerings, M&A and private transactions. Early in his career, Dr. Lu worked with McKinsey, serving global and domestic pharmaceutical and life science companies in their growth and financial strategies. He also worked in R&D at GSK in Philadelphia briefly. Dr. Lu holds a Ph.D. in Microbiology from Columbia University and an MBA from the University of Chicago.

John MacNair, Ph.D.

Analytical Program Lead
Spark Therapeutics

John received a Ph.D. in analytical chemistry from the University of North Carolina at Chapel Hill in 1998. For the next 22 years, John worked at Merck in vaccine analytical development. He contributed to the development of Pneumovax®23, Gardasil®, and VAXNEUVANCE™ commercial vaccine products. John then entered the field of gene therapy, joining Spark Therapeutics a year ago. At Spark, John leads a group of Analytical Project Leads. Outside of work, John enjoys family time, running, hiking, soccer, and learning to play the drums.

Mỹ Georgia Mahoney, Ph.D.

Professor, Vice Chair of Diversity and Inclusion
Thomas Jefferson University

Dr. Mahoney is a leading scientist with over 24 years of independent, funded research studying the mechanisms that control epithelial homeostasis and regeneration during wound healing and carcinogenesis. Her leadership is exemplified through various roles she holds including Vice Chair of Diversity and Inclusion for the Department of Dermatology and Cutaneous Biology and a member of the esteemed Admissions Committee for the Sidney Kimmel Medical School (SKMC) at Thomas Jefferson University. As the Vice Chair of Diversity

and Inclusion, Dr. Mahoney is a member of two Ph.D. programs, Biochemistry and Molecular Pharmacology and Genetics and Genomics and Cancer Biology. At the national level, she serves on the Committee on Diversity and Inclusion and has been nominated to serve as an upcoming Vice-President (elect) for the Society for Investigative Dermatology. Dr. Mahoney also serves as a mentor for the Philadelphia Chapters of the Association for Women in Science. At the international level, Dr. Mahoney is a Deputy Editor for the International Society for Extracellular Vesicle's *Journal of Extracellular Biology*.

Peter Marks, M.D., Ph.D.

Director, Center for Biologics Evaluation and Research,
FDA

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women's Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.

Yang Nan, Ph.D.

Vice President of Business Development
PersonGen BioTherapeutics (Suzhou)

Yang Nan completed his PhD study and post-doctoral training in Australia in early 1990s in Molecular Biology and human Genetics. Since then, he has been engaged in research, clinical application and business development in fields of genetic testing/sequencing and biomedicine. As the leading author, Dr Yang and the team identified that ACTN3 genotype is influencing muscle function and bone density in human, which have laid the foundation for genetics research on athletic performance and healthy aging. As one of the first scholars actively exploring the application of NGS technology in clinical diagnosis and treatment, He was granted the relevant patents in 2012. Yang Nan has been involved in establishing several start-up companies and research institutes in genetic testing and cellular immunotherapy, where he played roles in company operation, R&D leadership, and leading roles in marketing and business development. He worked for the Children's Hospital at Westmead (affiliated with Sydney University) for 15 years, he established a genetic testing service center in Heifei and worked for 5 years. Yang Nan has been awarded Hefei Friendship award (2020), Excellent Postgraduate Teaching award from Sydney University (2008), one of World 100 Great Scientific Discoveries from Discovery Magazine (2004), and several awards from Suzhou and Hefei.

Tatiana Nanda, Ph.D.

Head of Cell and Gene Drug Product Development
Center for Breakthrough Medicines

Tatiana Nanda, PhD has over 11 years of experience in biotherapeutics across MAbs and cell and gene therapies and is currently a Head of Cell and Gene Drug Product Development in Center for Breakthrough Medicines. In this role Tatiana is responsible for design and implementation of a diverse and client-focused Drug Product service portfolio and the establishment of internal formulation and manufacturing platforms. Prior to joining CBM, she was in Janssen, where she led the DP scientific strategy and execution of Oncology and Ocular compounds across multiple modalities including autologous CAR-T's and AAV gene therapies. She was also involved in the startup of J&J's commercial LVV manufacturing facility in Raritan, NJ. Prior to this, Tatiana worked at GSK in Biopharmaceutical Product Sciences. Tatiana has a BS in Microbiology from the University of Tennessee, a MS in Economics from the Moscow State University, and a PhD in Biophysics & Lifesciences from UT/ORNL.

Stephen G. Nappi

Associate Vice President, Technology Commercialization and Business Development
Temple University

Stephen Nappi has been in the business of commercializing university discoveries for the past 20 years. Mr. Nappi joined Temple University in 2008 as its Director of Technology Transfer and he currently serves as Associate Vice President of Technology Commercialization and Business Development within the Office of the Vice President for Research. In that role, Mr. Nappi heads the university's efforts to identify, protect and commercialize research-based discoveries while growing an ecosystem to support technology acceleration and startup creation. At Temple, Mr. Nappi benefits from a growing research environment that has led to the creation of over 35 startup companies in the past 10 years. These companies have successfully launched 5 products and collectively raised more than $160M in funding in the past 2 years. To support the university's startup portfolio, Mr. Nappi contributed to the formation of seed and venture-stage investment programs. Prior to joining Temple, Mr. Nappi spent 7 years at Florida Atlantic University in its Office of Technology Transfer. Mr. Nappi holds a BBA in business management and marketing from Florida Atlantic University. He is a member of AUTM and the Licensing Executive Society. Mr. Nappi is President Emeritus of BioStrategy Partners and continues to serve on its Board of Directors.

Yan G. Ni, Ph.D.

Executive Director of Biomarkers and Precision Medicine
Passage Bio

Dr. Yan Ni is an Executive Director of Biomarkers and Precision Medicine at Passage Bio. The Biomarkers and Precision Medicine team is responsible for the overall biomarker strategic planning and execution for all clinical and preclinical programs in the Passage Bio research portfolio. Before Passage Bio, Yan was an Associate Director at the Precision Medicine Group of Regeneron Pharmaceuticals and was responsible for clinical biomarker planning and implementation for multiple disease areas from First-in-human to phase III. Yan also worked in the BioAnalytical Sciences Department at Bristol-Myers Squibb for five years, where she honed her expertise in clinical biomarker assay development, validation, and outsourcing. Her industry career started at Merck Research Laboratories at Rahway, New Jersey. Yan actively volunteers for the American Association of Pharmaceutical Scientists (AAPS) and is a founding member on the Leadership teams of the AAPS Biomarkers and Precision Medicine Community and the Gene and Cell Therapeutic Product Communities. She holds several patents and is a co-author of several industry white papers in biomarker assay development and validation.

Tao Niu, Ph.D.

Associate Director, Clinical & Quantitative Pharmacology
Vertex Pharmaceuticals

Tao Niu has broad experience in clinical & quantitative pharmacology for rare diseases, particularly in viral and non-viral in vivo gene therapy. He is currently the quantitative pharmacology lead for a LNP encapsulated mRNA therapy in cystic fibrosis at Vertex. Prior to Vertex, Tao was the pharmacometrics lead for Wilson's disease (in vivo replacement gene therapy using AAV) at Pfizer.

Tao also has extensive experience in regulatory submissions and is a key driver in the approval of two drug products (TRIKAFTA® in cystic fibrosis and NGENLA® in pediatric growth hormone deficiency). He is a subject matter expert in biologics PK assay and immunogenicity. He is representing Vertex in the IQ consortium immunogenicity working group.

Tao holds a PhD in pharmaceutics from University of Houston, an MS in pharmacometrics from University of Maryland, and is currently working towards a second MS in data science from Georgia Tech.

Kurt Imhof

Vice President, Policy & Public Affairs
Life Sciences Pennsylvania

Kurt Imhof serves as Vice President, Policy and Public Affairs at Life Sciences Pennsylvania, the statewide trade association for the Commonwealth's life sciences community. In that role, Kurt advocates for policies that incentivize and support the development of medicines and technologies, and ensures public officials understand Pennsylvania's life science ecosystem and its positive affect on patients and the economy. Prior to Life Sciences Pennsylvania, Kurt spent nine years working for United States Senator Bob Casey (D-PA).

Wendy Pan, J.D.,Ph.D.

Partner
Goodwin Procter LLP

Wenseng "Wendy" Pan, JD & PhD, is a partner of Goodwin Procter, a leading internal law firm with top notch life sciences practices. She has advised biotech and pharmaceutical companies at all stages, addressing a broad spectrum of legal needs, from initial company formation, corporate governance, to growth stage financing, partnership and joint venture, to IPO. She has represented buyers, sellers, private equity and venture capital investors in mergers and acquisitions, stock and assets acquisitions/divestures, control acquisition, minority investments, going private, de-SPAC transactions. She has handled numerous strategic licensing and partnership deals between global pharmaceutical companies and biotech companies, involving small molecule, biologics, gene therapies, cell therapies, medical devices, diagnostic products. Apart from transactional practice, she also helps her clients in resolving contractual disputes in complicated life sciences partnership arrangements. Her deep legal experiences, coupled with her unparalleled understanding about the businesses and technologies and her pragmatic approach have won recognitions by IFLR1000 as a leading lawyer for M&A, Who's Who Legal: Life Sciences (Transactional). Wendy obtained her JD from Columbia University School of Law and a PhD in chemistry, also from Columbia. She is also a registered US patent attorney.

Jihoon (Jay) Park, Ph.D

Chief Operating Officer
TeraImmune, Inc.

Jihoon Park, PhD is a Chief Operating Officer (COO) and a co-founder of TeraImmune,Inc. He has a broad and solid background in biochemistry, with specific expertise in cell metabolism, cancer biology, and redox biology. He has been involved in multiple drug development projects by collaborating with pharmaceutical companies and proven mechanisms of action of drug candidates. He has accumulated his scientific experience from Chungnam National University and NHLBI, NIH. Dr. Park served an NIH-Korean Scientists Association (NIHKSA) as a vice president in 2015, and led a committee that hosts monthly seminars, annual conference and meetings linking NIH and Korean government officials. He is still voluntarily dedicating to NIHKSA as an external advisory council. He completed the Technology Transfer course at NIH to learn the commercialization pathway of the biological sciences to the market.

Chunping Qiao
Principal scientist
Regenxbio Inc.

Chunping has been working in adeno-associated virus (AAV) - mediated gene therapy for more than twenty years and has always positioned herself as an AAV virologist and a muscle biologist. The twenty years of research work have resulted in three investigational drugs that are currently in clinical trials. Chunping has initiated a new program RGX-202 at REGENXBIO which features a novel design of microdystrophin with CpG-depleted codon and an extended C-terminus domain. The RGX-202 has passed the Investigational New Drug (IND) application in last November.

Yuhong Qiu, Ph.D.
Vice President of Regulatory Affairs
Legend Biotech

Dr Yuhong Qiu has served as Vice President of Global Regulatory Affairs since May, 2018. Previously, Dr Qiu served as Executive Director of Regulatory Affairs at Novartis Oncology where she worked for 12 years with increasing responsibilities. She has broad regulatory expertise spanning across both small and large molecule (biologics) development. Dr Qiu has led numerous successful global regulatory filings from first-to-human studies to marketing authorization applications. Before joining Novartis Oncology, Dr Qiu worked for 8 years at Johnson & Johnson where she led a team of scientists in drug discovery and gained rich experience in drug candidate selection, characterization and preparation of nonclinical documents for first-in-human studies. Dr Qiu received her Doctor of Philosophy degree and completed her post-doctoral training from the Baylor College of Medicine in Houston, Texas, USA. She received her Bachelor of Science degree in biochemistry from Wuhan University, China.

Varun Renjen, M.D.
Managing Director, Life Science Strategy
KPMG LLP

Varun is a Managing Director in KPMG's Life Science Strategy practice in Short Hills, New Jersey. Varun is a physician with over 11 years of experience in strategy consulting in the life sciences industry with additional academic medical research experience. His areas of focus are commercial strategy, growth strategy, medical affairs and M&A for life science companies worldwide. He has supported both big pharma companies as well and emerging earlier stage companies on a variety of strategic issues. As a trained physician, Varun has worked and supported across all therapeutic areas focus and has been a clinical SME across projects. Varun works with companies on a variety of precision medicine projects including disease area strategies, biomarker development and identification, portfolio design, new product planning, indication prioritization, and M&A/BD&L activities. Varun's work in precision medicine has spanned several therapeutic areas including oncology, neurology, mental health, immunology, nephrology, cardiology, and metabolic diseases. Varun's work has spanned modalities including cell and gene therapy, antibodies, and small molecules. Varun joins KPMG from Blue Matter Consulting where he found and built their CNS Center of Excellence with and focused on CNS precision medicine approaches for a variety of disease states. He was previously at Guidehouse and the IMS Consulting group.

Richard H. Smith
Chief Operating Officer
Rockland Immunochemicals, Inc

Richard Smith joined Rockland's executive team in 2010 as the Chief Operating Officer and currently sits on its Board of Directors. Richard oversees key business affairs, from company strategy to day-to-day business operations, all while ensuring Rockland's value proposition is well understood by its customers and community. He is a key contributor to Rockland's growth and global expansion, leading Rockland's acquisition of interests in Abzyme Therapeutics, antibodies-online GmbH, Boqor Ventures, Pubgrade GmbH and others. He and his team negotiated and closed numerous partnership and collaborations across the life science industry. Richard has a significant history in business, regulatory affairs, and government. He was a senior partner at KPMG, holding many leadership roles in the U.S and internationally. He was a senior advisor in the Office of Chief Counsel of the Internal Revenue Service in the U.S. Department of Treasury. He is an expert in partnership and limited liability companies and their use, financing, and operations. He served as a lead advisor for many

joint ventures involving global interests between and among individual and corporate investors. Throughout his career, he has had the fortune to advise and/or run many small and medium-sized businesses.

Adam Snook, Ph.D.

Associate Professor
Thomas Jefferson University

Adam Snook received a B.S. in Pharmacology and Toxicology (2001) from the University of the Sciences and a Ph.D. in Immunology and Microbial Pathogenesis (2008) from Thomas Jefferson University. Dr. Snook was a founding member and served as the Director of Antibody Development for 5 years at Invisible Sentinel, Inc. a leading molecular solutions company specializing in food safety and a current subsidiary of bioMérieux. He joined the faculty at Thomas Jefferson University in 2013 in the Department of Pharmacology and Experimental Therapeutics where he is studying the mechanisms underlying colorectal cancer tumorigenesis and the interaction between cancer and the immune system to develop new options to prevent or treat gastrointestinal cancers. His work has led to 7 investigator-initiated clinical trials examining colorectal cancer chemoprevention, cancer vaccines, and CAR-T cell therapies. He is currently an Associate Professor in the Department of Pharmacology and Experimental Therapeutics with a secondary appointment in the Department of Microbiology and Immunology. He is an Assistant Program Leader of the Immune Cell Regulation and Targeting (IRT) Program of the Sidney Kimmel Cancer Center. He is also Director of the Clinical & Translational Research track of the JeffMD Scholarly Inquiry Program of the Sidney Kimmel Medical College.

Sarah Steltz

Vice President, Economic Competitiveness
Chamber of Commerce for Greater Philadelphia

As the Vice President, Economic Competitiveness, Sarah Steltz provides strategic direction and leadership in support of the Chamber's mission to enhance the Greater Philadelphia region's overall competitiveness by attracting and expanding companies, capital, and talent in key growth sectors. Prior to joining the Chamber in 2022, Sarah was the Deputy Commerce Director and Chief of Staff in the Department of Commerce for the City of Philadelphia. Sarah also served as University City District's (UCD) Vice President of Workforce Solutions and Executive Director of the West Philadelphia Skills Initiative (WPSI), a nationally recognized workforce development organization. Sarah joined UCD after ten years at Drexel University, ultimately serving as the Director, Workforce & Economic Inclusion. She holds a B.A. from Susquehanna University and an M.S. from Drexel University. She lives in South Philadelphia with her family.

Sumana Sundaramurthy, Ph.D.

Technical Account Manager
Sino Biological US Inc.

Sumana Sundaramurthy joined Sino Biological as a Technical Account Manager in early 2022, as a member of the CRO team supporting the various protein and antibody service platforms. She leads R&D projects from a number of industry and academic clients. Prior to joining Sino Biological, Sumana completed her doctoral studies in Cell and Developmental Biology at SUNY Upstate Medical University under Dr. David Pruyne, where she studied how formins regulated cytoskeleton development in striated muscles. She has presented her work at multiple national and local conferences. In addition to her academic pursuits, Sumana held various leadership positions supporting student life at Upstate. She is also passionate about biotech innovations and she interned at the Office of Innovation and Partnerships at SUNY-RF. She has been a member of ASCB and NYAS for more than five years, supporting career development initiatives, and currently, is also one of the co-chairs of the career subcommittee within COMPASS-ASCB. Sumana also holds Masters in Cell Biology from Illinois Institute of Technology and Bachelors in Biotechnology from Anna University. She has also worked for a preclinical CRO and few notable research groups at Loyola University, University of Chicago and Sanofi Pasteur



Lan Tang, Ph.D.

Reginal Business Development Head
GenScript ProBio USA

Lan Tang is Regional BD Head at GenScript ProBio, with 32 years of experience in the life science sector. She received her Ph.D. degree in Molecular Biology from Carnegie Mellon University, and completed fellowship at Yale University.



Mark Thompson, Ph.D.

Senior Business Development Manager
GenScript ProBio USA

Mark Thompson is Sr. Business Development Manager at GenScript ProBio, with 14 years of experience in the life science sector. He received his Ph.D. in Molecular and Cellular Biology from University of Arizona.

Sharon Tong, Ph.D.

Executive Director and US New Jersey Site Head
WuXi AppTec

Dr. Sharon Tong joined WuXi AppTec in 2014, and currently is Executive Director and serves as site head at the company's New Jersey location –which provides DMPK, Bioanalytical and In Vitro Biology services. During her time with the company, Dr. Tong has primarily focused on DMPK. Prior to her current role, she served as DMPK site head at the New Jersey location, and provided oversight of many DMPK areas in China. She has a proven track record of delivering high-quality DMPK packages, and establishing efficient operation models and state-of-the-art technology platforms. Dr. Tong has more than 20 years of experience working with large companies in the pharmaceutical and CRO industries, and a strong record of growth and cross-functional collaboration with both internal and external partners. Prior to joining WuXi AppTec, she was a director of DMPK at Merck Research Laboratories in New Jersey, gaining more than 17 years of experience in the field of ADME, PK and Bioanalytical testing. Dr. Tong received her B.S. in Chemistry from Fudan University in Shanghai, China. She received her Ph. D. in Analytical Science at the University of Wisconsin-Madison, and completed her post-Doctoral work at Cornell University.

Jim Wang, Ph.D.

Chief Regulatory Officer
Adverum Biotechnologies

Jim Wang, Ph.D., is the chief regulatory officer at Adverum Biotechnologies. Dr. Wang has more than 18 years of global experience managing full-spectrum drug development, marketing applications, and regulatory approvals for biologics, gene therapy, and device drug combination products. He served as vice president, global head of regulatory strategy at PTC Therapeutics, leading the planning/execution of global regulatory activities across all therapeutic areas focusing on rare disease. He provided oversight to a cross-functional team for the marketing application of a gene therapy product (eladocagene exuparvovec) treating AADC deficiency. He served as head of regulatory affairs strategy at Spark Therapeutics. He led the BLA/MAA submission and approval for LUXTURNA®, the first gene therapy product approved by FDA that targets an inherited disease (retinal dystrophy) caused by mutations in a specific gene (*RPE65*). Previously, he held various positions of increasing responsibility in regulatory affairs, as an executive director at Shire; senior director at Novo Nordisk, director at BMS; associate director at Sanofi-Aventis. He began his career working as a principal scientist at Pfizer (formerly Wyeth Pharmaceuticals). He earned his Ph.D. in Chemistry from the University of Illinois at Urbana-Champaign, an MBA from Pennsylvania State University, and BS from Jilin University in China.

Qizhao Wang, Ph.D.

Chief Technology Officer
AAVnerGene Inc.

Dr. Wang has more than 15 years of AAV vector development and gene therapy experience at Temple University (Weidong Xiao's Lab), Stanford University (Yang Hu's Lab) and Vigene Biosciences. His research mainly focuses on AAV vector development (for treatment of Hemophilia A and Glaucoma), AAV virology and AAV production.
Dr. Wang is the co-founder of AAVnerGene Inc, an innovative biotech company specializing in developing highly efficient AAV packaging technologies, and using the proprietary capsid screening platform (ATHENA I and II) to select the best AAV capsid for each target in a high-throughput manner.

Jill Weimer, Ph.D.

Chief Scientific Officer
Amicus Therapeutics

Dr. Jill Weimer has directed the science arm of Amicus Therapeutics since June 2019, first as the Senior Vice President of Discovery Research and Gene Therapy Science and more recently as the Chief Science Officer. Dr. Weimer is a developmental neuroscientist by training and started her academic research program at Sanford Research and the University of South Dakota in 2009 as Assistant Scientist/Assistant Professor, focused on the molecular mechanisms mediating development of the cerebral cortex and how disruption in these processes can lead to a whole host of neural pediatric disorders, including Batten's disease and Neurofibromatosis Type 1. Work in Dr. Weimer's lab led to the first ever gene therapy trial programs for CLN3 and CLN6 Batten disease. Today she plays a unique dual role, holding leadership positions with both Amicus and Sanford Research, serving most recently in the role of Senior Director of Therapeutic Development and Scientist at Sanford. Dr. Weimer grew up in north central Missouri and moved to upstate New York where she received her bachelor's degree and Ph.D. in neuroscience from the University of Rochester. She completed her postdoctoral training in the Neuroscience Research Center at the University of North Carolina in Chapel Hill with a focus on developmental neuroscience. Dr. Weimer also serves as a scientific advisor to a number of rare disease foundation as well as serving as the President of the Alumni Council for her alma mater, the University of Rochester School of Medicine and Dentistry.

David Weinstein, M.D., MMSc

Senior Vice President, Clinical Development
Passage Bio

Following his graduation from Harvard Medical School, Dr. Weinstein did a residency, chief residency, and fellowship in pediatric endocrinology at Boston Children's Hospital. He subsequently obtained a Masters in Clinical Investigation from Harvard and MIT, and became Director of the Glycogen Storage Disease Program at Boston Children's. In 2005, Dr. Weinstein moved to the University of Florida where he directed the GSD Program and became a tenured professor. He moved to the University of Connecticut in 2017 where his team launched the world's first gene therapy trial for GSD. In 2020, he left the academic world to serve as the medical lead for the GM1 gangliosidosis and metachromatic leukodystrophy gene therapy trials at Passage Bio. Dr. Weinstein has published over 100 publications on GSD and gene therapy. In 1989, he was named as one of the inaugural Goldwater Scholars. He is a former Jan Albrecht Award winner from the American Association for the Study of Liver Diseases, and he was the George Sacher Award winner from the Gerontological Society of America. In 2013, Dr. Weinstein was knighted in Poland and honored with the Order of the Smile international humanitarian award. He was also inducted in the Rare Disease Research Hall of Fame.

Marc Wenger, Ph.D.

Head of HT Technology and Lab Automation
Spark Therapeutics

Marc Wenger is the Head of HT Technology and Lab Automation (HTLA) at Spark Therapeutics where he leads the strategy and implementation of lab automation for Spark's Research and Technical Development and Operations (TD&O) organizations. He holds a B.S in Biology from Saint Joseph's University, M.S. in Chemistry from Lehigh University, and a Ph.D. in Biochemical Engineering from University College London. Prior to joining Spark, he spent 25 years in the Vaccine Bioprocess R&D at Merck & Co., Inc., holding roles of increasing responsibility in analytical and process development, including leadership roles in high throughput process development (HTPD), analytics (HTA), downstream PD, and CMC project management.



Weifeng Xu, Ph.D.

Director
Merck

Weifeng has been in the field of immunogenicity for more than 10 years. He is an active member in AAPS neutralization antibody (NAb) work group as well as EBF (European Bioanalysis Forum) NAb team; he is also co-leading the NAb assay drug tolerance subteam at AAPS. After join Merck at the end of 2018, Weifeng is now leading Cell Assay group within PCD Regulated Bioanalytics to develop immunogenicity assays for both biologics, vaccines, and cell therapy.

Haichen Yang, M.D.,, M.B.A.

Vice President, Clinical Research
Amicus Therapeutics

Dr. Yang is the President for Sino-American Pharmaceutical Professionals Association-Greater Philadelphia (SAPA-GP) for year 2022-23. She is an accomplished pharmaceutical executive and recognized clinical expert with more than 25 years of drug development experience in the fields of neurology, psychiatry, pain, and metabolic disorders. She has led or significantly contributed to clinical development that resulted in ten worldwide new drug and indication approvals, including Fycompa®, Keppra® (pediatric), and Luvox CR®. Dr. Yang is currently a Vice President Clinical Research at Amicus Therapeutics directing both small molecule and gene therapy clinical programs. She is previously a Vice President at ICON plc, where she provides strategic consulting services on drug development to top executives of biotech/pharma companies. Before that, she has worked for Eli Lilly, Solvay, UCB, and Eisai with increasing responsibility leading a range of clinical development programs. Dr. Yang has published 2 book chapters, more than 40 articles in peer-reviewed journals, and over 120 international meeting posters. She has been frequently invited to speak at high-profile professional conferences. She also serves as a committee member for multiple drug development societies and industry task forces.
Dr. Yang received her medical degree from Peking University Health Science Center (formerly Beijing Medical University) in China. She has a Master's degree in molecular biology from Indiana University Bloomington. She also received a MBA degree from Temple University Fox School of Business.

Tong-yuan Yang, Ph.D.

Senior Director
Janssen R&D

Dr. Tong-yuan Yang currently is Senior Scientific Director at Preclinical Sciences and Translational Safety, Janssen Research and Development, LLC, the pharmaceutical sector of Johnson & Johnson. He has over twenty years of experience in biopharmaceutics ranged from drug discovery, development to market approval. He manages a group of scientists to develop and validate biochemical, biological, and immunological assays

to enable characterization of pharmacokinetics (PK) and immunogenicity of biologics, CAR-T and gene therapy products in nonclinical and clinical settings. He is an active member of the American Association of Pharmaceutical Sciences (AAPS). He received his medical degree from Peking Medical University (Now Peking University Health Science Center) and Ph.D. in Molecular Virology from Pennsylvania State University College of Medicine where he also holds an adjunct professorship at Department of Pharmacology.

Bo Zhang, Ph.D.

Head of US Subsidiary
EdiGene

Dr. Bo Zhang has around 20 years of experience in research and drug development in both industry and academia. He joined EdiGene in 2020 as Head of US Subsidiary. Prior to joining EdiGene, he was Vice President of KLUS Pharma and focused on cell therapy and new technologies. Before that, he was Director of Development at Cobalt Biomedicine leading CAR-T and other cell/gene therapy programs, and R&D Director at OvaScience developing stem cell-based products. Prior to that, he held various oncology research and development positions at Merrimack Pharmaceuticals and Archemix.

Shuyuan Zhang, Ph.D.

Chief Technology Officer
Forecyte Bio Limited

Dr. Zhang worked continuously in the cell and gene therapy field for nearly 30 years since joining the World first gene therapy company in the early 1990s. Altogether, he worked in six innovative cell and gene therapy companies and led the companies process development and cGMP production for successful filing of more than 10 cell and gene therapy INDs with the FDA. He is a recognized expert in plasmid, viral vector (AAV, lentiviral, adenoviral, retroviral vector), and cell (CAR-T) product process development and cGMP production. He is the inventor of numerous manufacturing process patents and completed a gene therapy product BLA CMC filing. During his long career, he had close working relationships with many top CGT CDMO companies and learned the “best practices” in this field. This provides a solid technical foundation and competitiveness for Forecyte Bio as a new full-service cell gene therapy CDMO company.

Grace Zhou, Ph.D.

Chief Executive Officer; Chief Scientific Officer
ImmVira Group Company

Grace Zhou, is professor, co-founder, CEO and Chairman of ImmVira Group with over 25 years of experience in the academic research and pharmaceutical industry. Dr. Zhou was awarded the Women in Science Award by International Society for Antiviral Research in 2019 and received special governmental allowances of the PRC State Council in 1998.
Grace Zhou received her Ph. Degree from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences in 1998. She was a former associate professor of the Department of Microbiology at the University of Chicago. With her studies focused on the control of innate immune responses in herpesvirus infected cells, the molecular basis of oHSV latent infection, genetic engineering of anti-viral and therapeutic exosomes, Dr. Zhou is a national award-winning scientist with extensive years of academic and research experience in the field of oncology, virology and immunology. Prior to founding ImmVira, Dr. Zhou conducted research with the focus of her studies in the field of virology. In particular, she had conducted research in gene regulation during HSV-1 lytic and latent infection, HSV for cancer treatment in University of Chicago until 2013. She is the co-author of over 50 academic publications and the holder of over 17 patents.
ImmVira was founded by Grace Zhou and other 5 co-founders on May 2015 as a biotechnology company focused on genetically modified oncolytic viruses as potential cancer therapeutics. The company has developed science, technology and know-how to support ongoing research, development and commercialization of best in class oncolytic viruses on the OvPENS (OV+ Patent, Enabling, Novel & Safe) platform. Up-to-date, three innovative products are at clinical development (one at Phase II, two at Phase I) stage in China and USA.

Jingmin Zhou, Ph.D.

Chief Executive Officer
Genemagic Biosciences

Jingmin has more than 15 years of CMC experiences on AAV process development and manufacturing. Before he joined Genemagic Bio, he served different roles in both academia and industry, including Prevail (IPO 2019, Eli Lilly acquisition 2021), Spark (IPO 2015, Roche acquisition 2019), Intrexon (IPO 2013), and the Center for Cellular and Molecular therapeutics (CCMT) at CHOP. He has contributed multiple IND submissions and 1 BLA approval by FDA & EMA. Jingmin is leading Genemagic to prepare for IND applications to FDA soon.

De-Min Zhu, Ph.D.

President, Chief Executive Officer
Cureport

De-Min Zhu is the founder and CEO of Cureport, Inc. at Boston, a company inspiring in nanotechnologies. De-Min engaged himself in the innovations of lipid nanoparticles (LNP) for drug delivery in his decades of science and pharmaceutical careers. At Cureport, De-Min invented nPort^{TM} nanotechnologies that represents the most robust platform process in the world for manufacturing all type of liposomal products with prices particle size control from 20 to 200nm, direct scalability from milligram o kilograms, homogeneous morphology and particle size, and robust reproducibility. Recently, De-Min created a revolutionary LNP development strategy and has made exciting breakthroughs in LNP formulations for RNA/DNA delivery. The innovative LNPs increase mRNA transfection efficiency 10-30 folds, while dramatically reduced LNP toxicities as the ionizable lipid in the LNP is only a tiny fraction of the conventional LNPs.
De-Min completed his bachelor to Ph.D. in educations in Chemistry at Peking University. His earlier professional careers include more than 10 years of cross disciplinary scholar research at NIH and Harvard Medical School in biochemistry, biophysics, immunology, and cancer research. De-Min then joined Merck and then Pfizer serving as team heads leading biopharmaceutical formulation/process development for vaccines, biologics, oligonucleotide therapeutics, and as a core scientist of the companies' Science and Technology Committees for worldwide nanotechnology evaluation, due diligence, and licensing. At Pfizer De-Min invented the blanch tailed ionizable lipids for gene delivery, that design was utilized in the LNPs of the two FDA approved mRNA Covid-19 vaccines. De-Min published more than 30 peer-reviewed research articles. The equation he developed at HMS became the classic analysis for the determination of two-dimensional binding constant (2D K_d) of protein receptors /ligands in the contact area of T cells and antigen-presenting cells, and was recognized as Zhu-Golan Equation in the literature and books.

Bin Xu, Ph.D.

Associate Director
Frontage Laboratories

Bin Xu is an associate director who established and manages Genomics services in Frontage Laboratories Exton, PA. He has rich knowledge, expertise and leadership in genomics, gene and cell therapy, molecular biology and virology, both in industry and academia.

OBiO 和元生物®

GENE THERAPY CDMO

First Listed GCT CDMO in China (SSE: 688238.SH)

Industrialize Your Product at OBiO

Versatile Platform for Various Needs

130+
Process Development Projects

100+
Gene and Cell Therapy Programs

230+
Analytical Method Development Projects

Viral Vector
Adeno-associated Virus, Lentivirus

Oncolytic Virus
Adenovirus, Herpes Simplex Virus, Vaccinia Virus, Vesicular Stomatitis Virus, Newcastle Disease Virus

Cell Therapy
Autologous Cell Therapy, Allogenic Cell Therapy

Plasmid & Nucleotides
Plasmid, Mini-circle Plasmid, mRNA Plasmid

OBiO Technology (Shanghai) Corp., Ltd.

US Dept.: +1 857-385-6228
Main: +86 400-151-5198
Website: www.obio-tech.com
Business Inquiry: bd@obiosh.com
General Inquiry: oobio@obiosh.com

COMPLETE LABORATORY TESTING SERVICES

Bioanalytical | DMPK | Safety Assessment

labtesting.wuxiapptec.com

WuXi ADVANCED THERAPIES 药明生基 | 药明康德 WuXi AppTec

An integrated end-to-end solution for the global cell and gene therapy industry

We are a global Contract Testing Development and Manufacturing Organization (CTDMO) providing strategic partnership to cell and gene therapy pioneers

- Your single supplier from discovery to commercialization
- Work with us to accelerate your time to market

Advanced technologies, manufacturing and testing solutions

- Promoter and capsid optimization and cell line development
- Custom and off-the-shelf plasmid manufacture and supply
- Optimized platforms for viral vector and cell therapy manufacture
- Integrated analytical development and testing services
- Regulatory support packages

Accelerating success for the cell and gene therapy industry

To view more, visit:
advancedtherapies.com

OXGENE®
A WuXi Advanced Therapies Company


FORECYTE
Quality, Speed, Agility
Provide Proven CMC Solutions for Cell & Gene Therapies
4 x 4 Service Model
• Plasmids
• Viral Vectors
• Cell Products
• mRNAs
x
• R&D Support
• Process and Assay Development
• GMP (Preclinical, Clinical, Commercial)
• Regulatory CMC Filing
Secure and Flexible Supply Options
Maryland USA
· 17,000 SF
· 2 GMP suites
· Additional space reserved
Shanghai China
· 140,000 SF
· 14 GMP suites
Forecyte Bio Limited
Your TRUSTED CDMO in CGT
- WWW.FORECYTEBIO.COM -
Our Website


Delivering sophisticated formulations.
• Formulation Development for Poorly Soluble Drugs
• cGMP Manufacture for Clinical Materials
• CR, Parenteral & Topical Dosage Forms
OUR TECHNOLOGIES
EmulSol
AmorSol
NanoSol
ASCENDIA PHARMA
Making the impossible possible.
+1-732-640-0058
ascendiapharma.com

Bristol Myers Squibb™

Transforming patients' lives through science™

careers.bms.com

Serving Humanity

Patients are at the center of everything we do. They inspire us. They are the reason we come to work each day.

Powered by People

With a diverse and inclusive culture, we empower our people to bring their best ideas, drive innovation and achieve our mission to help patients prevail over serious diseases.

Work with Purpose

Join our team for inspiring work and career options that give you the opportunity to learn and grow professionally with talented and passionate colleagues.

8 People & Business Resource Groups with 12.5K global members.

Global presence in **50+** countries worldwide.

An Award Winning Company

FORTUNE THE WORLD'S MOST ADMIRED COMPANIES 2022

MILITARY FRIENDLY 2022 SILVER EMPLOYER

WORKING MOTHER 100 BEST COMPANIES 2019

BEST PLACES TO WORK 2022 for LGBTQ+ Equality 100% CORPORATE EQUALITY INDEX

ENERGY STAR AWARD 2022 PARTNER OF THE YEAR

Cureport

A Company leading
Lipid Nanoparticles Innovation & Process for Gene Delivery

LNP Innovation

possessing tremendous potential in mRNA/DNA vaccines, therapeutics, gene editing, and RNAi. What elevates Cureport's innovative LNP beyond the traditional LNP used in the COVID vaccines include:

1. 10–30× enhancement in mRNA/DNA delivery efficiency, both in vitro and in vivo.
2. Single and repetitive dosing.
3. An extremely low N/P ratio (0.5–1.0).
4. Up to a 90% reduction in ionizable lipid content.
5. 2.5–5.0 fold increase in mRNA/DNA loading.
6. The elimination of cytotoxicity.



nPort™ Technology
for liposome/LNP manufacturing.

Superior to Extrusion, T-mixing, Microfluidics





- **Flexible scalability, mg-kgs.**
- **Controllable particle size 20-200 nm.**
- **Homogeneous morphology and particle size.**
- **Robust reproducibility.**
- **Elimination of LNP bleb enhanced stability.**
- **Streamlined platform technology for all type LNP, RNA/DNA, peptides, small molecules**

Collaborations

Cureport has established collaborations with pharmaceuticals in the development of liposomal drugs, mRNA vaccines, mRNA therapeutics, and gene editing. WuxiApptec, the leading CDMO pharmaceutical in the world, has licensed Cureoport's nPort™ technology for nanomedcine development and GMP manufacturing. We are flexible and open minded for collaborations with business partners.

药明康德 WuXi AppTec · NCL Nanotechnology Characterization Laboratory · gsk · AMGEN · Penn

IVIEW Therapeutics Inc.
5 Cedar Brook Drive
Cranbury, NJ 08512
Tel: 609 773 8580
Website：www.iviewtherapeutics.com



RGC https://www.jneurosci.org/content/36/35.cover

iVIEW Therapeutics Inc. is a clinical-stage biotech company focusing on innovative therapy for the treatment of eye diseases. The company's product pipeline covers novel drug candidates for the treatment of acute conjunctivitis, dry eye, myopia, post cataract anti-inflammation and presbyopia. Recently, iView initiated the CGT programs with collaboration of well-known research institutions.

iVIEW Therapeutics is seeking highly motivated and talented Principal/Sr. scientists to join its growing team. iVIEW offers **Competitive Salary, Health Insurance including medical, dental and vision care, and Retirement Benefits including 401K plan, Profit Sharing Plan, plus Employee Incentive Plan.** If interested, please send your resume and cover letter to info@iviewinc.com. Opening position available immediately:

Principal Scientist/Senior Scientist - Gene Editing

- PhD with 5+ years of industry experience in cell and molecular biology or related discipline.
- Strong background in cell and molecular biology and excellent expertise in gene-editing techniques
- Demonstrated ability to lead and work effectively across multi-functional groups
- Demonstrated excellence in planning, executing, and analyzing experiments

Sr. Scientist, iPSC Derived Cell Therapy

- A Ph D with 2 years of relevant experience
- Background in stem cell biology focused on iPSC reprogramming with relevant publications

Admin Assistant or Office Manager

- A BS or BA degree or equivalent is required. Candidate with more than 5 years of administration management, basic accounting skills or human resource management experience preferred.

NeuExcell THERAPEUTICS

At NeuExcell, we are disrupting the dogma! The dogma is that once a neuron is gone, it's gone forever. We are disrupting that dogma through our **Astrocyte to Neuron (AtN)** conversion gene technology platform. We regenerate functional neurons to replace the ones that have been lost.

NeuExcell is a gene therapy company focusing on improving the lives of patients suffering from neurodegenerative diseases. Our disruptive technology focuses on regenerating neurons in the brain. This powerful platform has the potential to transform the lives of millions of patients suffering from serious debilitating neurological diseases.

The **NeuExcell** team is looking forward to moving into our corporate headquarters - Discovery Labs in King of Prussia, PA - to continue building our world-class team. Together, we strive to serve patients by transforming the promise of **AtN Platform** into therapies that have the power to restore health or save lives.



For more information, see https://neuexcell.com/ or contact Lori Gavrin @ lorigavrin@neuexcell.com


Medicilon
MEDICILON
www.medicilon.com
Fully Integrated Preclinical Drug Discovery and Development Services
Discovery Chemistry (FFS and FTE)
PROTACs, DEL, and AI-Enabled Drug Discovery
In vitro Biology, Structure Biology, and Protein Manufacture
API Development and CMC
ADMET, PK/PD, and Animal Models
Drug Safety Assessment and IND-Enabling Service
FDA
NMPA
EMA
TGA
E-mail: marketing@medicilon.com

Map


GLADWYNE
Frazer
BRYN MAWR
Devon
BERWYN
Ardmore
STRAFFORD
Paoli
Haverford
Kiosk
MALVERN
Centennial Ballroom III
EXECUTIVE BOARDROOM
ST DAVIDS
Centennial Ballroom II
Centennial Ballroom I
WAYNE
VILLANOVA
Grand Ballroom
Main Entrance